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ABSTRACT 
 
 The reductionist approach contributes greatly to our understanding of anticancer 
properties of phytonutrients, but in vitro studies demand concentrations that are 100-1000 
times higher than achievable in humans, producing results with little physiologic 
relevance, resulting in disappointing outcomes in clinical trials. However, maintaining 
these bioactives in the presence of other compounds originally derived from the 
food/extract of origin may synergistically lower the bioactive dose so translatability 
becomes feasible. The first objective of this study was to determine if bioefficacy of 
phytonutrients can be enhanced when used in combination at doses that are ineffective 
when used in isolation. In this project, proliferation of CWR22Rv1cells, HEK293 cells 
and expression of NF-kappa B was evaluated and synergy were assessed using Chou-
Talalay method when treated with turmeric, Chinese goldthread and their bioactives in 
isolation or in combination. Bioactives were not as potent as their extracts of origin. 
Combinations of herbal extracts and/or their isolated bioactives interacted synergistically 
and lowered effective concentrations to those similarly found in humans and may account 
for why foods/plant extracts are more likely to be beneficial against cancer compared 
with isolated components.  
 Turmeric and Chinese goldthread are two major components of a polyherbal 
mixture, Zyflamend, which has anti-prostate cancer (PCa) effects via multiple 
mechanisms. Zyflamend regulated fatty acid metabolism by inhibiting synthesis and 
enhancing oxidation in prostate cancer cells, suggesting AMP-activated protein kinase 
(AMPK), the master energy sensor of cells, as a potential target. Therefore, the second 
objective was to investigate whether the antiproliferative effects of Zyflamend were 
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mediated via AMPK activation. Our results showed that in castrate resistant PCa cells, 
Zyflamend activated AMPK, and in turn, regulated known downstream targets of AMPK, 
such as mammalian target of rapamycin complex 1 (mTORC1) and the phosphorylation 
of acetyl CoA carboxylase (ACC). The anti-proliferative effects of Zyflamend could be 
mimicked by AMPK activation and attenuated by AMPK inhibition. Thus, we concluded 
that AMPK activation contributes to the anti-PCa effect of Zyflamend.  These novel 
results, along with those published previously, provide a more complete picture of how 
this polyherbal mixture may complement conventional treatments based on its multiple 
mechanisms of action.  
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CHAPTER I  
INTRODUCTION 
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1.1 Prostate cancer 
Prostate cancer (PCa) is the most common internal malignancy diagnosed in men 
and the second highest cause of cancer death in males in the United States [1].  
1.1.1 Progression of prostate cancer 
Development of prostate cancer can be characterized by several clinical stages 
(Figure I.1) [2, 3]. It is widely accepted that prostatic intraepithelial neoplasia (PIN) is an 
initial step in the progression towards PCa [4, 5]. Notably, due to the strong association 
between high-grade PIN (HGPIN) and PCa, it is recognized as the precursor of PCa [6-8]. 
Progression of PCa is a slow process and it takes up to 10 years to manifest the disease 
from PIN [7, 9]. To evaluate the prognosis and progression of PCa, two parameters are 
commonly utilized.  One is the Gleason grade, which is an evaluation system for biopsy 
results. The other one is prostate specific antigen (PSA), a protein produced by prostate 
epithelial cells. Time dependent elevation of PSA is a sign for cancer progression [9]. 
PCa is considered ‘low grade’ when the Gleason score is between 2 and 6 [10], along 
with a low blood PSA level. Gleason score and PSA levels increase with tumor 
progression. Tumors with a Gleason score of ≥7 behave in a more aggressive manner and 
more readily metastasizes to secondary sites, such as bone and lymph nodes. PCa with 
Gleason scores higher than 7 can be categorized as an advanced form prostate cancer (Ad 
PCa). 
Androgens play an important role in prostate cancer progression. Advanced 
prostate cancer can be further distinguished based on hormone dependence. In early 
phases of advanced PCa, there is a dependence on the presence of androgens (androgen-
dependent growth) for promotion. In the absence of androgens, (referred to as androgen  
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Figure I.1 Progression of prostate cancer. 
Abbreviations: PIN, prostatic intraepithelial neoplasia; LGPIN, low-grade prostatic 
intraepithelial neoplasia; HGPIN, high-grade prostatic intraepithelial neoplasia; PSA, 
prostate specific antigen; PCa, prostate cancer; ADT, androgen deprivation therapy; 
CRPC, castrate resistant prostate cancer. 
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deprivation therapy, ADT), most tumors regress as indicated by a drop in PSA levels. 
However, overtime almost all androgen dependent tumors transition to an androgen-
independent type (castration resistant), typically within ~ 3-5 years. This stage is more 
likely to lead to a more terminal stage of PCa. The growth of the tumor in this phase is 
remarkably aggressive and is difficult to treat because of the location of the tumor (i.e., 
bone). Inevitably death occurs within one or two years (Figure I.1). [3, 9, 11, 12]  
1.1.2 Prostate cancer treatment 
Different kinds of strategies were generated to prevent or treat PCa. Due to the 
slow progression of the disease, the 5-year survival rates are 100% if diagnosed early, 
unless the disease progress to castrate resistant form. Therefore, diagnosis for early stage 
PCa is essential and critical for treatment and management. Besides traditional diagnosis 
methods like biopsy and the PSA test, a variety of new biomarkers are also used, 
including prostate health index (PHI, the score combining all types of PSA), RNA 
markers (PCA3, TMPRSS2-ETS, PTEN, etc.), circulating tumor cells (CTC), etc. [13, 
14].  
With regards to advanced forms of PCa, it is important to generate treatment 
strategies to prolong the life and increase survival, particularly following ADT [2, 9, 15]. 
ADT is the first line of care against Ad PCa [16]. The clinical practice guideline 
published by the American Society of Clinical Oncology recommends continuous ADT 
to both androgen dependent and independent Ad PCa [15]. It was first reported by 
Huggins and Hodges seventy years ago that suppressing serum androgen levels has 
dramatic clinical effects in men with Ad PCa [17]. ADT could be achieved by either 
surgical castration (orchiectomy) or pharmacologic castration. Despite the low physical 
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morbidity of orchiectomy, it is becoming less common to utilize this treatment in Ad PCa 
due to the psychological impact [16]. Pharmacologic castration can be achieved by 
inhibition of androgen receptor (AR) signaling, which includes suppression of luteinizing 
hormone-releasing hormone (LnRH antagonist), inhibition of androgen biosynthesis and 
inhibition of AR (AR antagonism) [18].  
Although ADT is widely used in treatment of Ad PCa and clearly shows benefit 
in improving quality of life in patients, there is no evidence showing a survival benefit of 
ADT for metastatic PCa [16]. Thus, it is important to generate new treatment strategies to 
prolong life and increase the survival rates of Ad PCa patients. 
1.2 Herbs and PCa treatment 
Prostate carcinogenesis is a long and multi-step process that normally takes 2-3 
decades to progress from its precancerous condition, thus providing a large window of 
opportunity to prevent or slow the disease process. As a result, PCa cancer is a gold 
model to investigate chemopreventive agents owing to the prevalence of the disease and 
its slow progression [13]. Among chemopreventive agents from natural sources, 
botanicals and herbs are receiving an increasing amount of attention due to their low 
adverse effects and potential anti-cancer properties. These natural products are gaining 
interest from patients as forms of complementary and alternative medicines during cancer 
treatment [14]. 
1.2.1 Epidemiology of Prostate Cancer 
Epidemiological research indicates that race is an important risk factor in the 
development of PCa. As reported by the American Cancer Society, the latest Cancer 
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Statistics show that African Americans have the highest incidence and death rates. 
Comparatively, these rates are much lower in Asian Americans, which have 3 times 
lower incidence rates and 5 times lower death rates than African Americans [1]. The diet 
of African Americans tends to contain more deep fried meat and lower amounts of fresh 
fruits and vegetables [21]. Worldwide ~2/3 cases of PCa are found in developed countries 
and cultures with a typical Western-style diet [22]. For example, PCa cases in India are 
about 35 times fewer than in the United States [23]. Interestingly, the same ethnic groups 
living in different regions also have different PCa incidence rates. Japanese living in the 
United States have higher PCa incidence rates compared with those living in Japan [24]. 
The PCa incidence rate of first generation Japanese immigrants is ~4 times higher than 
people from their hometown and this rate is almost the same as US-born residents [25]. 
1.2.2 Diet and Prostate Cancer 
One explanation for these data is that the components of diet, such as fruits, 
vegetables, spices, and herbs may influence the initiation and progression of PCa. A 
meta-analysis of case-control and cohort studies indicated that high adherence to the 
Mediterranean diet, rich in fruits and vegetables significantly reduced the risk of PCa by 
~4% [19]. In a 2 year US cohort study, 43,268 US males completed detailed food 
frequency questionnaires which included flavonoid-rich foods (tea, fruits, vegetables, soy, 
et al.). The total amount of flavonoids was calculated and an inverse trend of flavonoid 
intake and high-grade PCa was observed [20]. Similarly, in the Netherlands Cohort study 
spanning 17 years, involving 58,279 subjects, detailed dietary intakes were collected by 
questionnaires and dietary flavonoid intake and black tea consumption were associated 
with a significant reduction in the risk of Ad PCa [21]. Similar results were found in a 
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study of 250 Chinese PCa patients and 500 controls, where green vegetables and green 
tea were inversely associated with the risk of PCa [22]. 
1.2.3  Mechanisms of phytochemical action 
Pre-clinical studies using phytochemicals contribute greatly to our understanding 
of their mechanism of action. Phytochemicals, the non-essential nutrients found in fruits, 
vegetables and herbs, are commonly responsible for color and aroma of plants. 
Phytochemicals can be divided into 5 groups and the phenolics are the most important 
part of phytochemicals from our diet (Figure I.2) [23]. Although different phytochemicals 
have a variety of targets to interrupt cancer initiation and progression, there are several 
common mechanisms of actions [24-26] (Figure I.3):  
1. Preventing DNA-damage by scavenging reactive oxygen species (ROS) and 
procarcinogenic molecules [27, 28].  
2. Influencing epigenetics (methylation status of DNA and histone) by targeting 
the activity of various factors influencing epigenetics, such as DNA methyltransferase 
(DNMT), histone deacetylase (HDAC), etc. [29, 30].  
3. Altering mitogen-activated protein kinases (MAPKs) cascades, targeting 
extracellular-signal-regulated kinase (ERK) [31-33], JUN N-terminal kinase (JNK) and 
p38 or phosphoinositide-3-kinase (PI3K) and protein kinase B (PKB). 
4. Modifying activity of several transcription factors, such as activator protein-1 
(AP-1) and nuclear factor-κB (NF-κB), androgen receptor (particularly PCa), thus 
modifying the expression of cancer-related factors, such as COX-2 [34], IL-6, IL-8, 
VEGF, PSA [35], etc. 
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Figure I.2 Classification of dietary phytochemicals. Adapted from Ref [23] 
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Figure I.3 Mechanisms of anti-carcinogenesis actions of phytochemicals, redrawn 
from Ref. [36]. 
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5. Increasing cell cycle arrest by modulating key molecules involved in control of 
the cell cycle, such as cyclin D, p21, etc. [37].  
6. Increasing apoptosis by targeting caspase 3 and the Bcl-2 family [27, 38, 39]. 
These mechanisms are not separate from each other, but stimulate and support 
each other to form positive feedback loops, thus helping cancer cells to increase their 
ability to proliferate, resist cell death, and promote invasion and metastasis. Due to the 
interaction among multiple pathways, drugs targeting single genes result in resistance to 
therapy, sooner or later [40]. Moreover, it is common for targeted drugs to have serious 
side effects [29]. For these reasons, utilizing herbs and phytochemicals are playing a 
more important role in cancer prevention and treatment due to the low potential for side-
effects and multiple targeting characteristics. Two herbs that interest to us are turmeric 
and Chinese goldthread and their major bioactive compounds. 
1.2.4 Turmeric and cancer  
Turmeric (Curcuma longa) has been widely used to color and flavor foods 
worldwide for thousands of years. In Southeast Asian cuisine, turmeric rhizome, 
normally abbreviated as turmeric, is the predominant intergradient of curry powder.  In 
the West, it is predominantly used in pickles, mustard and other kinds of sauces. Besides 
use in the diet, turmeric is used medicinally in Traditional Chinese and Indian Medicine. 
This spice is used to treat colic, toothaches, and chest pains as an anti-inflammatory agent. 
It is also used to heal wounds and protect lining of the stomach. Moreover, turmeric is 
also used in the treatment of jaundice and to support liver function. Most importantly, 
turmeric is typically used in cancer treatment in Traditional Chinese medicine due to the 
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anti-‘blood stasis’ effect, where blood stasis refers to hematological disorders [41, 42]. 
As a promising natural product in ancient medicine, an increasing number of researches 
have begun to clarify the cellular and molecular mechanisms of the action of turmeric. 
1.2.4.1 In vitro studies 
In cell-based studies, turmeric has been shown to have anti-oxidant and anti-
mutagenic activities [43-48] (Table I.1) which may contribute to cancer prevention.  It 
inhibits proliferation and induces apoptosis by regulating multiple molecular targets and 
pathways, including the inhibition of NF-κB and STAT3 [49], inhibition of PGE2 release 
[50], and the increase of G2/M cell cycle arrest [51]. These functions explain, at least a 
part of why turmeric has been shown to suppress cancer progression and metastasis [42, 
49-55] (Table I.1). Turmeric’s anti-cancer effects have been shown to be applicable to 
many types of cancer (Table I.1). As summarized in Table I.1, oral and topical 
application of turmeric significantly inhibits tumorigenesis [46, 56-59]. At the molecular 
level, oral doses of turmeric decrease the activity of proinflammatory pathways (i.e., NF-
κB, PGE2, COX-2, NO) [58], increase apoptosis (i.e., Bcl2) [58] and increase cell cycle 
arrest (i.e., p21, p53 and cyclin D) [60]. 
1.2.4.2 In vivo studies 
Chronic myeloid leukemia (CML) is characterized by elevated levels of nitric 
oxide (NO). In patients with CML, co-treatment of turmeric (5 g t.i.d. for 6 weeks) with 
chemotherapy (imatinib) resulted in lower levels of NO compared with imatinib alone. 
No significant side effects were found from the addition of turmeric at a dose of 15 g/day 
[61].  These studies suggest efficacy of turmeric on cancer related biomarkers with no 
reported side effects.  However, to obtain stronger evidence and clarify the molecular 
12 
 
Table I.1 Cellular and molecular mechnisms of turmeric 
Cell type Dose, duration Molecular target conclusion 
Tumor 
prevention 
   
Anti-oxidant    
In vitro assay -, 30 min - Exhibited anti-oxidant activity in in vitro assays [43, 44] 
Renal epithelial  100 µg/ml, 3 h - Inhibited lipid degradation and peroxidation caused by H2O2 [45] 
Anti-mutagenic    
S. typhimurium -  Exhibited anti-mutagenic activity against direct mutagens [46] 
S. typhimurium 2 mg/plate, 48 h  Exhibited anti-mutagenic activity against environmental mutagens [47] 
Beef patties 0.2%, 10 min Heterocyclic 
amines (HCAs) 
Inhibited mutagen (HCAs) generation during cooking process [48] 
Cancer 
suppression 
   
Decrease cell 
viability 
   
Chinese Hamster 
Ovary/lymphocy
te 
0.4 mg/ml, 30 
min 
- Inhibited the growth both cell lines [52] 
Pancreatic 
carcinoma 
IC50: 1-1.22 
µg/ml, 72 h 
  NF-κB, STAT3 Exhibited superior cytotoxicity compared to curcumin and synergistically 
enhanced effects of gemcitabine [53] 
Multiple cancer 25-100 µg/ml, 
up to 48 h 
  NF-κB, STAT3 
  Bax, DR4, DR5 
Exhibited anti-proliferative activities and induced apoptosis; more potent 
than curcumin; and enhanced effects of chemotherapeutic agents [49, 54] 
Leukemia/liver 
carcinoma 
IC50: 0.92-15.2 
µg/ml, - 
TNF-alpha, PGE2 Exhibited anti-inflammatory activity against oxidative stimulus [50, 55]  
Colon carcinoma 50-500 µg/ml, 
72 h 
Caspase-8, 9, 3, 
cyclin B1, CDK1 
Exhibited apoptosis induction and G2/M cell cycle arrest activities [51] 
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mechanism regarding the anti-cancer effect of turmeric, randomized, placebo-controlled, 
double blind clinical trials are required. 
1.2.4.3 Phytochemicals in turmeric 
Phytochemicals in turmeric can be roughly categorized into two groups. 
Curcuminoids account for about 3% to 5% of the dry weight of turmeric, and contributes 
to its yellow color [36]. The most common curcuminoid in turmeric is curcumin. The 
other group is the essential oil which is responsible for the aromatic taste and smell of 
turmeric. Dried turmeric normally yields 1.5%-5% essential oil and the most abundant 
compound is ar-turmerone [42]. 
1.2.4.4 Curcumin and prostate cancer 
Curcumin, o-methoxyphenol derivative, is the most widely studied bioactive 
compound in turmeric. Its anti-PCa effects have been extensively studied. In cell based 
studies, curcumin decreases cell viability of both androgen-dependent (LNCaP) and 
androgen-independent (PC3) PCa cells with an IC50 value of ~30 µM [62]. It can 
interfere with growth factor signaling pathways by down-regulating epidermal growth 
factor-receptor (EGF-R) [63] and AR [64, 65]. Curcumin also induces cell cycle arrest 
and apoptosis of PCa cells by inhibiting NF-κB and AP-1[65], down-regulating c-Jun [64] 
and cyclin D [66]. Epigenetic modification is also a target. Gene chip results indicated 
that curcumin changed the transcription level of over 100 genes by >4-fold in androgen 
dependent (LNCaP) PCa cells and about 40 genes in androgen independent (C4-2B) PCa 
cells [67]. The potential mechanism for epigenetic modification is illustrated in Figure I.4 
[68]. Treating LNCaP PCa cells with 5 µM curcumin for 24 hr decreased total HDAC 
activity and methylation of histone 3 at the promoter regions of targeted tumor suppressor  
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Figure I.4 Mechanisms of curcumin on gene expression, redrawn from Ref [68]. 
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genes like Neurog1 which is commonly hypermethylated and silenced in PCa cells [69]. 
Curcumin may also prevent PCa. Curcumin prevents malignant transformation of 
prostate epithelial cells induced by TCDD, a highly toxic pro-carcinogenic molecule [70]. 
Curcumin inhibits the elevation of cytochrome P450 by decreasing nuclear levels of 
arylhydrocarbon receptor (AhR) and AhR nuclear translocator (ARNT), protecting DNA 
damage from TCDD treatment, and thus preventing malignant transformation. In addition, 
the Hedgehog signaling pathway was also been shown to be inhibited by curcumin in 
PCa both in vitro and in vivo [71].  
Preclinical xenograft models of PCa support results from cell culture studies. 
Using a LNCaP xenograft model, nude mice were treated with diets containing 2% 
curcumin (w/w) for up to 6 weeks. Curcumin inhibited proliferation, induced apoptosis 
and inhibited angiogenesis in vivo [72]. Using DU-145 cells in a xenograft animal model, 
curcumin significantly decreased the tumor volume and induced apoptosis by increasing 
caspase-3 activity and inhibited metastasis through inhibiting MMP activity [73]. 
Although numerous studies show preclinical efficacy of curcumin, most clinical studies 
are limited to phase I trials to clarify the safety and bioavailability of curcumin. Single 
high oral doses (up to 12 g) of curcumin are well tolerated by healthy volunteers [74]. In 
addition, oral doses up to 8 mg/day for 3 months did not show any toxicity [75].  In spite 
of the high tolerance of curcumin, poor systemic bioavailability restricts it from being a 
proven clinical treatment. Unfortunately, even at oral doses up to 12 g, serum levels have 
been limited to concentrations in the low nM range [74]. This low bioavailability may be 
due to poor solubility, rapid metabolism, and short half-life [13]. 
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1.2.4.5 Turmerone and cancer 
Curcumin is not the only bioactive compound in turmeric. Thus far, there are 
about 235 compounds identified in this botanical [76]. One important component of 
curcumin-free turmeric (CFT) is turmeric oil, with ar-turmerone being its most abundant 
compound (31%) [77]. Although its effectiveness on inhibiting proliferation is not as 
potent as curcumin, ar-turmerone can still decrease viability of DU-145 PCa cell by ~10% 
after 72 hr treatment at a concentration of 100 µM [78]. This compound also shows anti-
oxidant, anti-inflammatory and anti-carcinogenic effect in other cell models. Sera et al 
reported that ar-turmerone suppressed inflammatory cytokines interferon (IFN)-γ and IL-
2 in CD4 T cells [79]. It decreased the expression of COX-2 and MMP-9 by interrupting 
NF-κB, PI3K/Akt, and ERK 1/2 pathways, and inhibited invasion, migration, and colony 
formation of MDA-MB-231 (breast cancer) cells [80]. In vivo studies or clinical trials 
have yet to be conducted to test its anti-carcinogenic effect and clinical application of ar-
turmerone requires further investigation.  
1.2.5 Chinese goldthread and cancer  
Chinese goldthread (CG) (Coptis chinensis) has been used as an herbal medicine 
in Asia for over 2000 years and it is still commonly used in Chinese medicine. In TCM, 
CG is widely used to remove damp-heat which roughly translates to inflammation in 
modern medicine [81]. It is the most important ingredient of many famous anti-
inflammatory Chinese compound formulae such as Sanhuang Xieyin decoction and 
Huanglian Jiedu decoction [82, 83]. Because inflammation is an important hallmark of 
cancer [40], CG is appealing for its potential anti-carcinogenic effect.  It has been used in 
studies involving many cancer types such as breast, colon, liver, pancreatic and 
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neuroblastoma [81, 84, 85]. DNA microarray data indicate that CG can modify 27 genes 
of pancreatic cancer [86]. CG can also inhibit NF-κB activity and its translocation 
stimulated by TNF-α in human keratinocytes [87].  Feeding rabbits CG at a dose of 0.14 
g/kg body weight can decrease serum IL-6 levels, which may in part, explain the anti-
inflammatory effect [88]. More studies are needed to clarify the mechanisms of anti-
inflammatory and anti-cancer effects of CG. 
1.2.5.1 Berberine and prostate cancer 
There are more than 8 kinds of isoquinolin alkaloids identified in CG [89]. 
Berberine is considered the most active component and its anti-inflammatory and anti-
carcinogenic effect has been widely studied [81, 90, 91]. Berberine significantly 
decreases the viability of multiple PCa cell lines, including LNCaP, CWR22Rv1, PC3, 
C4-2B and DU-145 with IC50 values in the range of 50-100 µM [92, 93]. To decrease cell 
viability, berberine increases G1 arrest by decreasing cyclin D1/D2/E, decreasing activity 
of CDK2/4/6, increasing p21/p27 and binding of CDK with p21/p27 [92]. G2/M cell 
cycle arrest is also induced by exposure of 50 µM berberine for 24 hr [94], and berberine 
increases PCa cell apoptosis by generating ROS and increasing the activity of caspase-3 
[92, 95, 96]. Androgen receptor is also regulated by berberine. It is reported that 100 µM 
berberine significantly reduces the expression of AR and PSA concentration in LNCaP 
and CWR22Rv1 cells after 24 hr treatment [93]. Berberine also significantly suppresses 
the growth of PCa cell in animal model [97]. Although the anti-cancer effects of 
berberine are encouraging in cell culture and animal models, clinical studies have not 
yielded any positive results. One reason may be its low bioavailability. For example, the 
mean maximum plasma concentration in 20 healthy volunteers given an oral dose of 400 
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mg of berberine was only ~ 0.4 ng/ml (1.2 nM), a concentration dramatically lower than 
those used in vitro (50-100 µM) [98].  
1.2.5.2 Coptisine and cancer 
Besides berberine, another phytochemical in CG, coptisine, also shows potential 
as an anti-cancer compound. It has been reported that coptisine inhibits the proliferation 
of hepatoma and leukemia cell lines with IC50 values varying from 0.6-14.1 µg/mL (1.8-
44 µM) [85]. It may also suppress as adhesion, migration and invasion of breast cancer 
cells via down-regulation of MMP-2 [99]. There are no reported studies involving 
coptisine in PCa.  
1.3 Disappointed results of clinical trials using pure phytochemicals 
  In vitro studies using pure phytochemicals derived from natural products help to 
clarify potential mechanisms of their anti-cancer effects; and although epidemiological 
studies clearly show a relationship between diet and cancer, results from clinical trials 
using phytonutrients are disappointing [100].  
Using resveratrol as an example, more than 1000 papers about resveratrol have 
been published in PubMed every year since 2010 and a multitude of molecular targets 
were found in preclinical studies (Figure I.5) [101]. These encouraging data suggest that 
resveratrol has been identified as a ‘potential’ chemopreventive agent for cancer with 
identifiable mechanisms of action. However, it is difficult to translate these results to 
humans. In a phase I randomized, double-blind study, 6 patients with colorectal cancer 
and hepatic metastasis were equally divided into control and experimental groups, where 
the experimental group was given 5 g resveratrol daily for 10-21 days. Resveratrol had no  
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Figure I.5 Molecular targets of resveratrol, redrawn from Ref [101]. 
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effect on circulating PGE2 and VEGF levels. In addition, resveratrol had no effects on 
well-known cancer-related biomarkers in liver tissue, such as IGF-1, Ki-67, p-Akt, p-
GSK3, p-ERK, p-JNK, β-catenin, and Bcl-2 [102]. 
1.3.1 Low bioavailability of phytochemicals  
One explanation is low bioavailability of phytochemicals, in general. 
Concentrations used in vitro are much higher than physiological concentrations 
achievable in humans. Using the phytonutrients used in this dissertation, Table I.2 and 
Table I.3 summarize this point where the mean IC50 concentrations of a variety of 
phytochemicals observed in a variety of cancer cell lines are 41 µM, 21 µM, >243 µM 
and 29 µM for: berberine, curcumin, ar-turmerone and coptisine, respectively. This is in 
dramatic contrast to humans provided gram quantifies of oral doses, where the 
serum/plasma concentrations are in the nM range (Table I.3).  
1.3.1.1 Digestion, absorption and excretion of phytochemicals 
Bioavailability of phytochemicals is related to the digestion, absorption, 
transportation and excretion. In botanicals, polyphenols are the most abundant 
phytochemicals. Typically, they are associated with endoplasmic reticulum, accumulate 
in vacuoles as conjugated forms, or linked to the cell walls via ester bonds. Most 
polyphenols are released from food matrices in the stomach or small intestines after 
intake. It has been reported that ~80% of flavonoids, a member of polyphenol family, are 
ingested as glycosides and removal of these sugar moieties are required prior to uptake by 
enterocytes. The free forms are taken up by enterocytes through passive diffusion, 
facilitated or active transport. Most of the polyphenols are re-conjugated in the form of 
glucuronides, sulfates or methylated prior to reaching the apical side of enterocyte. They 
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Table I.2 In vitro antiproliferative effects of berberine, curcumin, coptisine and ar-turmerone in a variety of cell lines based on 
IC50 concentrations (µM) 
Berberine [103] Curcumin ar-Turmerone Coptisine 
Cell Line IC50 (µM) Cell Line IC50(µM
) 
Ref Cell Line IC50 
(µM) 
Ref Cell Line IC50 
(µM) 
Ref 
HeLa 20 KBM-5 3.8 [104] MDA-MB-
231 
>100 [105] MDA-MB-
231 
78 [106] 
L1210 10 Jurkat 4.3 [104]  50 [80] HeLa 35 [107] 
A431 75 U266 7.6 [104]  >462 [108] MDA-MB-
468 
63 [106] 
DU145 100 A549 17 [104] MCF-7 >100 [105] HepG2 203 [109] 
U937 15 U87 15 [110]  >50 [80]  3.5 [85] 
MCF7 20 T98G 31 [110]  >462 [108] Hep3B 5.4 [85] 
CL1-5 7.5 PC3 32 [111] HepG2 >100 [105] SK-Hep1 1.4 [85] 
Colo205 80 LNCaP 53 [112]  300 [113] PLC/PRF/5 6.6 [85] 
C6 10 DU145 30 [73]  >432 [108] K562 7.2 [85] 
U-87 20 MCF-7 20 [114] Hep3B 564 [113] U937 1.5 [85] 
VSMC 200 MCF7/LCC
2 
20 [114] Huh-7 472 [113] Raji 0.6 [85] 
B16 3 MCF7/LCC
9 
20 [114] U937 185 [115] P3H1 11 [85] 
RPMI 8226 5 Mean 21  K562 185 [116] LoVo 2.7 [117] 
MDA-MB-
231 
25    L1210 116 [116] LoVo/Dx 12.5 [117] 
NPC-HK1 200    U937 111 [116] HT29 1.5 [117] 
EAC 2    RB1-2H3 162 [116] Mean 29  
YES-6 3    Mean >243     
NIH-3T3 30          
A7r5 23          
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Table I.2 Continued 
Berberine [103] Curcumin ar-Turmerone Coptisine 
HepG2 39          
Hep3B 45          
Sk-Hepl 10          
PLC/PRF/5 40          
K562 43          
U937 28          
P3H1 24          
Raji 1.8          
L929 120          
Mean 41          
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Table I.3 Effect of oral dosing of curcumin from a single dose (g) to 24 weeks 
treatment (g/d) on maximum serum/plasma concentrations (nM) of curcumin and 
its metabolic derivatives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Ref Dose (g) Curcumin (nM) 
(underivatized) 
Total Curcumoids (nM) 
(curcumin +derivatives) 
LC or GC Mass Sepctral Analysis 
[118] 0.45 nd  
 1.8 nd  
 368 nd-11 35.8 
[119] 4 21 149 
[120] 0.03 4.9  
HPLC-UV Detection 
[74] 2 nd  
[75] 4 nd  
 6 nd  
 8 nd  
 10 137  
 12 157  
 4 510  
 6 630  
 8 1770  
[121] 0.45 <3 <3 
 1.8 <3 <3 
 3.6 <3 <3 
[122] 0.036 nd nd 
 0.072 nd nd 
 0.108 nd nd 
 0.144 nd nd 
 0.18 nd nd 
[123] 2 nd  
[124] 12 nd  
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also can be secreted back into the lumen of the gut. After entering the bloodstream, they 
are bound to plasma proteins, such as albumin, or lipoprotein particles, such as LDL and 
HDL. The majority of polyphenols prefer to circulate bound to proteins. LDL and HDL 
prefer to incorporate apolar polyphenols. Further phase I/II metabolism of polyphenols 
and their conjugated forms occur in liver.  Polar polyphenols are typically excreted via 
kidney while the majority of apolar compounds are excreted via the bile [125] (Figure 
I.6). 
1.3.1.2 Low oral bioavailability of phytochemicals 
Several reasons may contribute to the low oral bioavailability of phytochemicals. 
1. Apolar polyphenols, such as flavonoids and isoflavonoids, need to be mixed 
with bile salts in small intestine for absorption due to their poor solubility in aqueous, 
which significantly dampens their bioaccessiblity [126].  
2. Most polyphenols, except for those with low molecular weights, require cell 
surface transporters for absorption, although not all transporters have been identified. 
[127].  
3. Following absorption by enterocytes, most polyphenolics are quickly 
conjugated before they reach the apical side of the enterocyte. This metabolic step may 
facilitate secretion of the derivatives of polyphenols back into the lumen of the gut, 
enhance degradation and/or result in their accumulation in the cells [127].  
4. Tissue distribution is also important for bioavailability of phytochemicals. For 
example, curcumin could only be detected in liver and kidney tissues after an oral dose of  
400 mg [128].  
25 
 
 
Figure I.6 Digestion and absorption of polyphenols.  
Redrawn from http://healthfavo.com/digestive-system-for-kids.html 
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1.3.2 Interactions among phytochemicals  
Besides low bioavailability, interactions among phytochemicals and other 
nutrients may also contribute to the differential effects observed between phytochemicals 
and foods in which they are found [125]. For example, β-carotene is rich in fruits and 
vegetables. High intake of fruits and vegetables rich in β-carotene is inversely related to 
the risk of lung cancer [129]. It is reasonable to hypothesize that supplementation of β-
carotene could decrease the incidence of lung cancer. However, in a randomized, double-
blind, placebo-controlled trial involving 29,133 male smokers in Finland (over 5-8 years), 
β-carotene supplementation significantly increased the incidence of lung cancer [130]. 
This result was recapitulated in another study, which showed that combination of β-
carotene and vitamin A increased the incidence of lung cancer by about 28% [131]. It has 
been suggested that compared its anti-oxidant effect in fruits and vegetable, β-carotene in 
isolation may shift to a pro-oxidant when used at high doses [132].  
These data suggest that the effects of isolated phytochemicals may have effects 
that are divergent from the natural products from which they are derived. As suggested 
by Todd et al “The role of nutrition in cancer is more complicated than originally thought. 
Any potential benefits derived from dietary sources are likely to be due to a combination 
of factors rather than single components acting in isolation” [133]. Dietary sources like 
botanicals contain many phytochemicals and these phytochemicals may interact 
synergistically. For example, phytochemicals in cranberries include flavonol glycosides, 
anthocyanins, proanthocyanidins and phenolic acids with synergistic effects against 
multiple cancer cell lines [134]. Similarly, pomegranate fractions act synergistically when 
suppressing PCa cell growth [135]; and the efficacy of ginger extract (GE), with a mix of 
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4 other most abundant bioactives, was more potent than the individual components in a 
PCa xenograft model. It was suggested that the higher bioavailability of the 
phytochemicals in GE may have contributed to this effect [136]. Some of these effects 
can be summarized in Table I.4 and illustrated in Figure I.7. 
1.3.2.1 Synergy and phytochemicals 
Synergy can be explained by the following: 
1. The bioavailability of phytochemicals may be enhanced by other 
phytochemicals from the same natural product.  For example, turmeric exhibits superior 
cytotoxicity compared with curcumin in multiple cancer cell lines including pancreatic, 
colon, and breast [49, 53]. The combination of turmeric oil and curcumin can increase the 
bioavailability of curcumin by ~ 7-8 fold [137]. Poly E, a multi-polyphenolic 
combination from green tea is more potent in inhibiting tumor growth compared with 
EGCG, the most widely studied phytochemical extracted from green tea [138-140]. Poly 
E could inhibit lung tumorigenesis in mice where EGCG had no effect [141]. Regarding 
bioavailability, the levels of EGCG were higher in human plasma samples when taken 
orally as the Poly E mixture compared with EGCG alone [142]. Similarly, EC, another 
phytochemical in green tea, can enhance the cell incorporation of EGCG in lung cancer 
cells [143]. Phytochemicals from different herbs appear to have the same interaction. In a 
phase I clinical trial, 6 healthy man were divided into two groups (n=3/group) and 
provide oral doses of curcumin with or without piperine. Plasma from the combination 
group showed that combination of 2 g curcumin ( from turmeric) and 5 mg of piperine 
(from black pepper) can double the bioavailability of curcumin compared with curcumin 
alone [123].  
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Table I.4 Synergistic effect among phytochemicals from different herbs 
models Phytochemicals  Doses, 
duration 
conclusion 
In vitro 
assay 
Curcumin 
+resveratrol 
5 µM each, 3 
min 
Exhibited synergistic effects on 
antioxidant activities [144] 
Cell lines 
Breast 
cancer 
Curcumin 
+carnosic acid 
4 µg/mL 
each, 24 hr 
Synergistically decreased viability 
of multiple BCa cell lines [145]  
 Curcumin + DHA < 50 µM Synergistically decreased viability 
of SK-BR-3 cell [146] 
 Curcumin + 
emodin 
N/A Synergistically decreased cell 
viability [147] 
 EGCG, resveratrol, 
γ-tocotrienol 
10 µM each Synergistically decreased NQO1, 
additively suppress cell 
proliferation, reduce cyclin D1 and 
Bcl-2 [148] 
 6 phytochemicals 
cocktail  
< 10 mM  Synergistically decreased cell 
viability and affected multiple 
molecular targets [149] 
Oral 
epithelial 
Curcumin + EGCG N/A Synergistically decreased viability 
of malignant epithelial cells [150] 
Prostate 
cancer 
EGCG, genistein, 
curcumin 
2.5 µM each Synergistically decreased viability 
of CWR22Rv1 cells in 10% FBS 
medium [151] 
Human 
trial 
Curcumin 
+piperine 
1500+15 
mg/d, 28 d 
Bioavailability of curcumin was 
enhanced by piperine [123, 152]   
mice Curcumin 
+resveratrol 
5 µM each, 
10 week 
Bioavailability of curcumin was 
enhanced by resveratrol [153] 
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Figure I.7 Mechanisms of synergistic effect among phytochemicals. Redrawn from 
ref [154]. 
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2. Phytochemicals from the same herb or different herbs may have “synergistic 
multi-target effects”, meaning the phytochemicals affect multiple targets, and therefore 
cooperate synergistically (Figure I.7) [154]. For example, the anti-inflammatory 
properties of Chinese goldthread (CG) are more potent than berberine, where CG 
inhibited nuclear translocation of NF-κB, but berberine had no effect [87]. Similarly, 
phytochemicals from different herbs may also synergistically. EGCG (from green tea), 
genistein (from soy) and quercetin (fruits, vegetables, grains) can synergistically decrease 
the viability of PCa cells. Different molecular targets have been identified for each 
phytochemical. For example, EGCG was found to decrease AR expression; genistein 
could increase p53, NADPH dehydrogenase and quinone 1 (NQO1); and quercetin could 
decrease both AR and increase NQO1. When these phytochemicals were used in 
combination, all the molecular targets (AR, p53, NQO1) were affected in a synergistic 
manner [151]. 
3. One phytochemical may eliminate or neutralize the adverse effects of another 
phytochemical when used in combination. Although, at this time no direct evidence 
proves this hypothesis, this is commonly believed to be the rationale, in part, for the 
formulation of traditional Chinese herbals. More work is needed to verify this hypothesis 
[154].  
1.4 Traditional Chinese Medicine (TCM) and cancer 
Cancer is one of the leading causes of death in the world [155]. In Asia, it is 
common to use TCM as a complementary and alternative therapy to improve the quality 
of a cancer patient’s life [41]. In TCM, cancer can be explained by ‘damp-heat’ and 
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‘blood stasis’ [41]. Damp-heat can be interpreted as long term inflammation in 
relationship to Western medicine [81], and blood stasis refers to the poor blood 
circulation, erythrocyte aggregation, exudation and hemorrhage [156]. Damp-heat and 
blood stasis is believed to interact with each other, thus promoting the development and 
metastasis of cancer. Herbal medicine is an important part of TCM. Chinese goldthread is 
one of the most common herbs used to remove damp-heat in TCM, accounting for anti-
inflammatory effect of CG [81]. Turmeric is typically used as a blood-activating and 
stasis-resolving medicine in cancer therapy [41, 156] (Figure I.8). Their combination is 
believed to act synergistically based on TCM. However, this effect has yet to be verified. 
1.5 Evaluation of synergy 
To quantitate synergistic effects, several mathematic methods have been 
developed. Of these, ‘Chou-Talalay’ is a commonly used method to measure the 
synergistic effects of chemopreventive compounds [157]. Over 40 papers using Chou-
Talalay have been published since 2013, with synergistic effects of chemoprevention 
drugs tested in multiple cancer cell lines (i.e., prostate, lung, ovarian, and breast 
carcinoma) [158-163]. Chou-Talalay is based on the median-effect equation and the 
theoretical basis of this method is illustrated in Figure I.9. The Chou-Talalay analysis 
utilizes two outcomes to differentiate synergy, antagonism or additive effects. One is the 
combination index (CI). If the CI is <1, the effect of the combination is synergistic, and 
the greater difference from “1” the greater the synergy. If the CI is = 1, the effect is 
additive, and if it is > 1, there is antagonism. The other is Dose Reduction Index (DRI), 
which tells us to what extent one compound can enhance the effectiveness of another  
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Figure I.8 Mechanisms of goldthread and turmeric anti-cancer effect in TCM. 
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Figure I.9 Theroic basis of Chou-Talalay method, with author’s permission. 
34 
 
compound at a given ratio and concentration, that is, how many fold the effective 
concentration of each compound may be reduced compared with the concentration of the 
compound in isolation [164]. CompuSyn® is the software developed by Chou et al. 
(2005) which utilizes the Chou-Talalay method. This software can generate dose 
dependent curves of each drug and their combinations, and calculate CI and DRI. The 
handbook of this software provides detailed experimental design for testing synergistic 
effects of different cancer chemoprevention drugs.  Thus, CoumpuSyn® can be used to 
evaluate the synergistic effects individual phytochemicals or combinations of herbal 
extracts from which they are derived. 
1.6 Cell models for prostate cancer research 
Cell models are commonly used to investigate the mechanisms of phytochemicals 
because they are easy to handle and manipulate, and because of their homogeneity, 
reproducibility, availability and variety. Most cancer cell lines were generated from 
aggressive and metastatic tumors [165]. Generally, there are two kinds of cell lines as 
models related to advanced PCa (Ad PCa), androgen-dependent (LNCaP, CWR22) and 
those that are androgen-independent (PC3, DU-145, CWR22Rv1). Due to the complexity 
of tumors in vivo, it is critical to choose an appropriate cell model based on objectives of 
each study. With regards to advanced forms of PCa, it is important to generate treatment 
strategies to prolong the life and increase survival, particularly following ADT. For this 
reason, we believe androgen-independent cell lines are better choices than androgen-
dependent ones.  In addition, cell models need to represent the basic characters of the 
diseases of interest. There are two important components associated with androgen-
independent PCa. One is PSA which is used as a biomarker for monitoring the recurrence 
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and progression of Ad PCa. The other one involves the mutation of the AR. Typically, 
AR expression is detectable in PCa tissues that are castrate resistant, whereby the growth 
does not require the presence of androgens [166, 167]. Moreover, it is common to 
observe mutations in the AR, a characteristic of the hormone refractory phenotype in Ad 
PCa [168]. PC3 and DU-145 are two commonly used androgen-independent PCa cell 
lines; however, neither produces PSA nor expresses AR, while CWR22Rv1 PCa cells 
process both characteristics. As such, CWR22Rv1 cells are commonly selected as a 
model for castrate-resistant PCa.  
CWR22Rv1 is a cell line derived from relapsed CWR22 PCa cells [169]. This cell 
line produces PSA and can survive in medium with or without androgens.  The AR 
expressed by CWR22Rv1 cell has two isoforms. One isoform has a mutation on DNA 
binding site and the other one mutated in the ligand binding domain. These two types of 
AR are constitutively activated when these cells are cultured in medium without 
androgens [170]. As such, CWR22Rv1cells are used as a cell model when studying Ad 
PCa following ADT.  
To explore the interaction of phytochemicals, we also used a cell line (HEK293 
cells) commonly used as a tool for expression vectors [171].  This cell line was originally 
derived from human embryonic kidney cells and was developed in Alex van der Eb’s 
laboratory in early 1970s [172]. Because they are easy to handle and transfect, HEK293 
cells are commonly used in cell biology research for these reasons. One important use of 
this cell line is transfection of a luciferase reporter by Lipofectamin® to test the 
transcriptional activity of targeting genes [173]. HEK293 is also used as a vector for the 
propagation of adenovirus. 
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1.7 Zyflamend 
Zyflamend is a combination of the extracts of ten commonly used herbs ((holy 
basil (Ocimum sanctum), turmeric (Curcuma longa), ginger (Zingiber officinale), green 
tea (Camellia sinensis), rosemary (Rosmarinus officinalis), hu zhang (Polygonum 
cuspidatum), barberry (Berberis vulgaris), oregano (Origanum vulgare), baikal skullcap 
(Scutellaria baicalensis), and Chinese goldthread (Coptis chinensis)) (Table I.5) [174, 
175]. The extracts are blended with beeswax and extra virgin olive oil and encapsulated 
in bovine spongiform encephalopathy (BSE) free gelatin (data provided by the 
manufacturer). This product has been on the market in 10 countries and regions for over 
10 years and no serious adverse events have been reported. Many of the herbs in 
Zyflamend have been used for thousands of years. Rosemary, turmeric, ginger and 
oregano are “generally recognized as Safe” (GRAS) (21 CFR 182.10 and 182.20) when 
used in food.  
1.7.1 Quality control of Zyflamend  
Zyflamend delivers herbs in a concentrated form not as isolated phytochemicals. 
Manufacturing of Zyflamend fully complies with Good Manufacturing Practices (GMP) 
as mandated in 21 CFR § 111 by the Food and Drug Administration (FDA). Fourier 
transform infrared spectroscopy (FTIR) is used by suppliers for verification of the herbal 
components to confirm the identity of the raw materials. The raw materials from each 
supplier are also verified by independent laboratories using a variety of analytical 
approaches, such as high performance liquid chromatography (HPLC), thin layer 
chromatography (TLC) and mass spectrometry (MS). Heavy metals, pesticides, and 
microbes are also targets analyzed for by both supplier and a third party laboratories. For  
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Table I.5 Specifications for active ingredients and excipients in Zyflamend [176] 
Botanical Part used  Method of 
extraction 
Marker/component specifications 
Rosemary 
(Rosmarinus 
officinalis) 
Leaf Supercritical CO2 Diterpene phenols (22%–24%), 
Essential oils (3%–5%) 
 Water and 
alcohol 
Diterpene phenols (24%–26%) 
Ginger 
(Zingiber officinale) 
Rhizome Supercritical CO2 Pungent compounds (24–35%), 
Zingiberene (≥8%) 
 Water and 
alcohol 
Pungent compounds≥3% 
Turmeric 
(Curcuma longa) 
Rhizome Water and 
alcohol 
Curcuminoids (≥11%) 
 Supercritical 
CO2, water 
Curcumin (≥0.5%), Total essential 
oil with α- and 
β-turmerone (70%–90%) 
Holy Basil 
(Ocimum sanctum) 
Leaves Water and 
alcohol 
Ursolic acid (2%–3%) 
Green tea  
(Camellia sinensis) 
Leaves Water Polyphenols (≥45%) 
Hu zhang 
(Polygonum 
cuspidatum) 
Radix & 
Rhizome 
Water and 
alcohol 
Resveratrol (≥8%) 
Chinese goldthread  
(Coptis chinensis) 
Root Water and 
alcohol 
Berberine (≥6%) 
Barberry  
(Berberis vulgaris) 
Root 
bark 
Water and 
alcohol 
Berberine (≥6%) 
Oregano,  
(Origanum vulgare) 
Leaf Supercritical 
CO2, water 
Essential oils (8%–12%), Phenolic 
antioxidants (≥4.5%) 
Baikal skullcap  
(Scutellaria 
baicalensis) 
Root Water and 
alcohol 
Baicalin (≥17%), Baicalein 
(≥1.5%), Wogonin (≥0.4%) 
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quality control purposes, select bioactive compounds in each extract must be maintained 
within certain ranges, as summarized in Table I.5.  
1.7.2 Zyflamend and its anti-cancer effects in pre-clinical and clinical studies 
Many of the bioactive phytochemicals found in the extracts of botanicals (i.e., 
curcumin, berberine, EGCG, resveratrol, baicalein, etc.) have been shown to be effective 
anti-cancer agents in vitro and many of their mechanisms of action have been elucidated 
[13, 24, 71, 177, 178]. Therefore, it is logical to think that the combination of these 
bioactives could have synergistic or additive effect for PCa treatment. Zyflamend has 
been reported to improve the outcome of HG-PIN (a commonly accepted precursor of 
PCa) with no serious adverse events or toxicities reported when taken orally up to 18 
months [179, 180]. It one study, 48% of subjects diagnosed with HG-PIN had a 25 to 50% 
decrease in PSA levels and a reduction of NF-κB in HGPIN following 18 months of 
Zyflamend treatment [179]. In preclinical models, more systematic studies have been 
conducted investigating its potential mechanisms of action, with PCa being a common 
target. In a murine xenograft model fed Zyflamend at human equivalent doses, it 
inhibited growth of tumors derived from androgen dependent and independent PCa cells. 
When Zyflamend was couple with hormone ablation (ADT), regression of tumor size 
accelerated, along with PSA levels compared with ADT alone [176]. At the molecular 
level, Zyflamend has been shown to decrease the protein levels of AR and a variety of 
HDACs [176]. Zyflamend treatment has been shown to reduce cell viability in PrEC, 
RWPE-1, LNCaP, CWR22Rv1 and PC3 cell lines [175, 181-183]. In LNCaP cells, it 
decreased PSA secretion and the activity of COX-1and COX-2, reduced the expression 
and protein stability of AR, and increased expression of p21 [181, 184]. In CWR22Rv1 
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cells, Zyflamend reduced expression of AR, IGF-1R, class I and II HDACs, elevated 
CBP/p300, p21 and p27 [175, 182]. In PC3 cells, Zyflamend has also been shown to 
inhibit the arachidonic acid pathway by targeting 5-LOX and 12-LOX [183]. Zyflamend 
also has anticancer properties in other experimental cancer models, i.e., bone, skin, mouth, 
pancreas and kidney [185-189], and multiple molecular targets have been identified. For 
example, the NF-κB activation and downstream signaling of NF-κB are modulated by 
Zyflamend in bone cancer [174, 185]. In pancreatic cancer, Zyflamend inhibited the 
activity of NF-κB, COX-2, VEGF, etc.[189]. Moreover, Zyflamend inhibited melanoma 
cell growth, migration, and expression of iNOS and COX-2, and induced cell apoptosis 
[186].  
1.8 Metabolic alternation in cancer 
Limitless replication is one important hallmark of cancer [190]. To support this 
characteristic, a large number of metabolic alterations happen in cancer cells and a major 
one is a shift from catabolic to anabolic metabolism (Figure I.10) [191], including 
increased macronutrients synthesis [192, 193] and reduced β-oxidation [194].  
1.8.1 Increased macronutrients synthesis 
To support the growth of rapidly proliferating cells, there is an increased need for 
macronutrients including proteins, nucleic acids and fatty acids. For example, protein 
turnover is ~2 fold higher in lung cancer patients than in healthy controls [192]. Protein 
turnover in malnourished cancer patients is more than 30% higher than malnourished 
patients with benign disease [193]. Furthermore, deregulation of protein synthesis is 
related to transformation of cancer cells [195]. Similarly, DNA synthesis is also  
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Figure I.10 Metabolism alternations in cancer cells. 
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commonly elevated in cancer cells. Thymidylate synthase, essential for DNA synthesis, 
is elevated in multiple human cancers [196]. 
Increase of de novo fatty acid synthesis is another characteristic of cancer cells. 
Normal cells prefer to use exogenous lipids to synthesize new structural lipids, whereas  
de novo fatty acid synthesis is primarily found in lipogenic tissues (liver and adipose 
tissue) and is highly dependent on nutritional status [197]. However, in cancer cells this 
pathway is upregulated and these cells are less responsive to dietary changes.  The 
activity of fatty acid synthase (FASN), a key enzyme involved in de novo fatty acid 
synthesis, is overexpressed in majority of human malignancies such as prostate, breast, 
colorectum, stomach and lung [198, 199].  
1.8.1.1 Elevation of protein synthesis in PCa 
The elevation of protein synthesis in PCa is generally due, in part, to the 
upregulation of mammalian target of rapamycin (mTOR), which is induced by PI3K-Akt-
mTOR pathway (Figure I.11). This pathway is initiated by the binding of ligands to 
growth factor receptors, such as platelet derived growth factor (PDGF), insulin-like 
growth factor (IGF), epidermal growth factor (EGF), etc. Following receptor activation, 
PI3K is recruited and activated by phosphorylation, and in turn phosphorylates 
phosphatidylinositol-4, 5-diphosphate (PIP2) to generate phosphatidylinositol-3, 4, 5-
triphosphate (PIP3). Activated PIP3 can bind to phosphoinositide-dependent protein 
kinase 1 (PDK1) which activates Akt (also known as protein kinase B, PKB) by 
phosphorylation. p-Akt can then activate one of its major downstream targets, mTOR, 
increasing protein synthesis and promoting cell growth and proliferation. Akt can also 
activate AR in the absence of androgens, and this is believed to be involved in the relapse  
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Figure I.11 AMPK signaling pathways. 
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of CRPC [200] (Figure I.11). It is reported that this pathway is up-regulated in about a 
half of PCa [200]. Activation of Akt by detecting phosphorylated Akt (p-Akt) at pS473 
can be found in almost all PIN and invasive PCa samples [201-203]. Moreover, the level 
of p-Akt is positively related with Gleason grades and PSA level [204-206].  
The activity PI3K can be inhibited by phosphatase and tensin homolog (PTEN) 
which convert PIP3 back to PIP2. Mutation/deletion of PTEN, which encodes PTEN, can 
be found in ~30% of primary PCa and in ~60% of metastatic PCa. Moreover, copy loss 
of PTEN is more frequently found in CRPC [201].   
mTOR, one of the central regulators of cell growth, responds to both nutrients and 
growth factors [207].  There are two kinds of signaling complexes involving mTOR, 
mTORC1 and mTORC2, which have distinct compositions and functions. mTORC1 is 
involved in regulating cell growth, angiogenesis and metabolism [208]. There are 4 
subunits contained in mTORC1 complex, regulatory associated protein of mTOR (raptor), 
PRAS40, GβL and mTOR. Within these subunits, raptor acts like a ‘scaffold’ protein, 
and plays a critical role in recruiting substrates of mTORC1, such as 4EBP1 and 
ribosomal S6 kinase (S6K) [209]. GβL stabilizes the combination of mTOR and raptor, 
acting as a positive regulator of the activity of mTORC1 complex [210]. Activated 
mTORC1 complex can remove 4EBP1 from translation initiation factor eIF4E and 
activate S6K by phosphorylation, which promote translation of a number of cell growth 
regulators (i.e. cyclin D) and biogenesis of ribosome [211, 212]. As the result of 
mTORC1 complex, protein synthesis is elevated and tumorigenesis is enhanced. 
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1.8.1.2 Elevation of de novo fatty acid synthesis in PCa 
The key enzymes involved in de novo fatty acid synthesis are ATP citrate lyase 
(ACLY), acetyl-CoA carboxylase (ACC) and FASN. At the beginning of this process, 
citrate is exported from the mitochondria and is converted to acetyl-CoA by ACLY. ACC 
then converts acetyl-CoA to malonyl-CoA and its carbon skeleton is used by FASN to 
produce palmitate. Among these enzymes, ACC is the rate-limiting step for fatty acid 
synthesis and FASN is the committed step that is commonly up-regulated in both primary 
and advanced forms of PCa. There is a positive relationship between FASN level and 
PCa progression and metastases [213, 214].  Interestingly, the transcription of ACLY, 
ACC and FASN can be regulated by the same transcriptional regulator, sterol response 
element binding protein-1c (SREBP-1c) [215, 216].  It has been reported that SREBP-1c 
is positively correlated with PCa progression [217]. Besides increasing transcription [214, 
218], up-regulating FASN can also be achieved by increasing gene copy number [219] 
and increasing protein stabilization [220] in PCa. 
1.8.2 Reduction of β-oxidation 
Increase of de novo fatty acid synthesis also impairs the rate of β-oxidation. 
Carnitine palmitoyl transferase-1 (CPT-1) is the rate-limiting enzyme that transfers long-
chain fatty acids from the cytosol to the mitochondria for oxidation. The activity of CPT-
1 can be inhibited by malonyl-CoA, which is commonly elevated in cancer cells due to 
the over-activation of ACC [221]. It has been reported that CPT-1 is commonly 
deregulated in multiple experimental and clinical cancer models, impairing β-oxidation in 
cancer cells (Figure I.11) [194]. 
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1.9 Crosstalk between AKT and SREBP1 pathways in prostate 
cancer 
Elevation of protein synthesis and de novo fatty acid synthesis are not 
independent. mTOR and FASN pathways can support and stimulate each other, thus 
promote cancer progression and metastasis (Figure I.11). Newly synthesized fatty acids 
tend to partition into lipid rafts [222], which provide platforms for protein-protein 
interaction, thus activating signaling cascades like PI3K [223]. Moreover, FASN pathway 
can also be up-regulated by Akt-mTOR pathway via multiple mechanisms.  
1. mTORC1 can directly induce the translation of ACC and FASN with no change 
in their mRNA level [224].  
2. mTORC1 can stimulate FASN pathway by increasing the expression of 
SREBP-1 and accumulating mature SREBP-1 in cells [225].  
3. Akt can up-regulate SREBP-1 by activating the ARr. In PCa, the AR is an 
important regulator for SREBP-1 expression. In addition, Akt can activate the AR in the 
absence of its ligand, which plays an important role in CRPC.  
4. Akt can directly phosphorylate ACLY, increasing its activity [226].  
High levels of FASN in PCa are correlated with the phosphorylation and nuclear 
accumulation of Akt [203].  
Several specific inhibitors of mTORC1 or FASN have been shown promising 
preclinical results. However, systematic use of these inhibitors in the clinic is hampered 
due to the emergence of survival feedback loops and severe side effects [227, 228]. For 
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example, rapamycin, an mTORC1 inhibitor can induce the activities of PI3K and Akt 
[229-231], and enhance lipogenesis by inducing FASN [232]. FASN inhibition results in 
unwarranted weight loss and thus was precluded from clinical use  
1.10 AMP-activated protein kinase 
1.10.1 Structure of AMP-activated protein kinase 
AMP-activated protein kinase (AMPK) is one of the central regulators of cellular 
and organismal metabolism in eukaryotes. In humans, AMPK exists as an obligate 
heterotrimer, containing a catalytic subunit (α) and two regulatory subunits (β and γ). The 
activity of AMPK complex can be enhanced by more than 100 fold when Thr172 of the α 
subunit is phosphorylated by upstream kinases. There are two major kinases that activate 
AMPK, liver kinase B1 (LKB1) and Ca
2+
/CaM-dependent protein kinase kinase β 
(CaMKKβ). Increased AMP/ATP or ADP/ATP ratio can stimulate the phosphorylation of 
AMPK provided by LKB1. AMP or ADP can directly bind to the γ subunit of AMPK, 
thus promoting phosphorylation and inhibiting dephosphorylation. Besides responding to 
AMP/ADP, AMPK can also be activated by CaMKKβ responding to the increase of 
intracellular level of Ca
2+
. [233, 234] 
1.10.2 AMP-activated protein kinase maintains energy homeostasis of cells 
Once activated, AMPK can turn on ATP-generating pathways and turn off ATP-
consuming pathways [216, 235], thus switching the metabolic states from anabolism to 
catabolism. Modulations by AMPK can be achieved in an acute manner via 
phosphorylation of metabolic enzymes and in a chronic manner via modifying the 
transcription levels of these enzymes. AMPK inhibits the activity of mTORC1 by directly 
phosphorylating raptor (regulatory associated protein of mTORC1) [236], thus inhibiting 
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protein synthesis. AMPK can also inhibit lipogenesis via down-regulating activity of 
ACC/FASN pathway. ACC can be inhibited by AMPK via direct phosphorylation. 
Inhibition of ACC can increase the level of acetyl-CoA and decrease the level malonyl-
CoA, which in turn increases the activity of CPT-1, thus increasing β-oxidation. AMPK 
can also inhibit the expression of FASN by down-regulating the transcriptional regulator, 
SREBP-1c [215, 216, 237-239]. (Figure I.11) 
1.10.3 AMPK is a target for drugs and phytochemicals with effects on cancer 
AMPK is commonly deregulated in metabolic syndrome [240], which is 
associated with increased risk of high grade PCa [216, 241]. In addition, Akt pathway is 
commonly over-activated in Ad PCa due to the nonfunctional PTEN, thus inhibiting the 
activity of AMPK [201, 242]. Moreover, inactivation of AMPK increases proliferation, 
migration and invasion of androgen-independent PCa cells. With inactivation of AMPK, 
the expression of several oncogenes such as IGF-1 and IGF-1R are up regulated, whereas 
several cancer suppressor genes such as p53 and p21 are down regulated [243]. 
Altogether, these findings indicate that AMPK may play a role in PCa progression and 
metastasis and activation of AMPK is a potential strategy for PCa treatment.  
Multiple AMPK activators have shown anti-PCa properties in epidemiologic and 
pre-clinical studies [238, 244-247].  Metformin, a mainstream therapeutic drug for type II 
diabetes, reduces the risk of PCa in Caucasians by 44% and this anti-cancer effect is 
partly attributed to AMPK activation [239]. Metformin can increase AMP/ATP ratio in 
cells via impairing respiratory chain, thus activating AMPK [228]. Another AMPK 
activator, aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) also shows 
anti-PCa effects in both androgen-dependent and independent PCa cells [243, 244]. 
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AICAR mimics the molecular structure of AMP, thus directly activating AMPK by 
binding to γ subunit. Some mechanisms of anti-PCa actions of AICAR have been 
elucidated. As an AMPK activator, AICAR inhibits activity of both mTORC1/S6K and 
ACC/FASN pathways, thus inhibiting protein and fatty acid synthesis in Ad PCa cells 
[243, 244].   
AMPK is also a target of multiple phytochemicals such as curcumin, berberine, 
resveratrol, and EGCG [228, 233], which may contribute to the anti-cancer action of 
these bioactive compounds. These phytochemicals indirectly activate AMPK via different 
mechanisms. For example, Curcumin can activate LKB1, and EGCG can activate 
CaMKKβ, the upstream kinases of AMPK [228, 248]; berberine can increase AMP/ATP 
via inhibiting mitochondrial function [249]; and resveratrol can inhibit ATP synthesis and 
increase activity of LKB1 [228, 233]. All of these phytochemicals are components of 
Zyflamend, and this it is logical to hypothesize that AMPK is a target of Zyflamend. 
1.11 Summary 
In summary, it seems intuitive that combination of bioactives in botanicals is far 
more effective than an individual bioactive in isolation. However, there is no systematic 
approach to evaluate the synergistic actions in complex mixture such as Zyflamend. To 
address this issue, we picked two widely used herbs (turmeric and Chinese goldthread) 
from Zyflamend and determined if synergy could explain the enhanced effect of (a) the 
combination of herbs over isolated bioactives derived from those herbs, (b) the 
combination of bioactives over isolated bioactives derived from the same herb 
(companion compounds), (c) the combination of herbs over individual herbs, (d) the 
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combination of bioactives from different herbs over the isolated bioactives, and (e) 
whether these synergistic effects on proliferation can apply at the molecular level.  
There are always concerns regarding reproducibility and quality control of herbal 
mixtures due to the complex components of these products. The quality control in the 
preparation of these extracts has been described in detail elsewhere [176]. Assurance of 
that quality control has been verified by the corroborative reproducible results generated 
at different times, with different lots, in multiple laboratories, under different 
circumstances, using similar and different cell lines with similar concentrations [175, 176, 
179-189, 250]. Previously generated results suggested that multiple pathways may be 
involved in mechanisms of Zyflamend action. Preliminary evidence from our laboratory 
demonstrating that Zyflamend down regulates SREBP-1c and FASN transcription and 
increases fatty acid oxidation suggests it may be regulating AMPK, a new discovery 
related to this blend of bioactives. Therefore, the objective of this study was to determine 
if Zyflamend could modulate AMPK activation and its downstream targets, biomarkers 
of fatty acid synthesis and mTORC1 signaling. These novel results, along with those 
published previously, can provide a more complete picture as to how blends of natural 
products may complement conventional treatments as a result of multiple mechanisms of 
action. 
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CHAPTER II  
TURMERIC AND CHINESE GOLDTHREAD SYNERGISTICALLY 
INHIBIT PROSTATE CANCER CELL PROLIFERATION AND NF-
KB SIGNALING 
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Abstract 
Pre-clinical studies using bioactive compounds from botanicals appear to offer 
some protection against cancer. Research using single bioactives contributes greatly to 
our understanding of their mechanism of action, but in vitro studies demand 
concentrations that are higher than achievable in humans (µM), producing results with 
questionable physiologic relevance. However, maintaining these bioactives in the 
presence of other compounds originally derived from the food or extract of origin may 
synergistically lower the bioactive dose so translatability becomes feasible. The objective 
of this study was to determine if bio-efficacy of phytonutrients can be enhanced when 
used in combination even at doses that are ineffective for any compound when used in 
isolation. The anti-proliferative and molecular effects of herbs (turmeric and Chinese 
goldthread) and their bioactives (curcumin and ar-turmerone, berberine and coptisine, 
respectively) were determined in isolation and in combination. Using CWR22Rv1 and 
HEK293 cells, cell proliferation (as assessed by the MTT assay) and NF-κB promoter 
activity (using a luciferase reporter construct) were evaluated and synergy of action was 
assessed by the Chou-Talalay method utilizing CompuSyn
®
 software. Turmeric and 
Chinese goldthread act synergistically (combination index<1) when inhibiting cell 
proliferation with all cell lines tested. The synergy of action of combinations of 
companion bioactives from the same herb (i.e., curcumin/ar-turmerone and 
berberine/coptisine) and bioactives from different herbs (i.e., curcumin/berberine) help to 
explain why turmeric and Chinese goldthread are more effective than their major 
bioactives in isolation. At the molecule level, curcumin+ar-turmerone and 
curcumin+coptisine synergistically attenuated TNFα-stimulated NF-κB promoter activity. 
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Even compounds with poor efficacy become more biologically active in the presence of 
companion compounds. Importantly, the effects of combining any two bioactives or 
herbal extracts were highly synergistic at concentrations approaching physiological 
significance (nanomolar). These results suggest that bioactives in combination (as plant 
extracts or isolated compounds) are highly synergistic at the cellular and molecular level 
at physiologically relevant concentrations. These data help to explain why complex 
mixtures of botanicals may be more efficacious than their bioactives in isolation. 
2.1 Introduction 
Research exploring the use of natural products, such as botanicals, herbs, herbal 
extracts, and their isolated bioactives are becoming increasingly appealing because of 
their potential efficacy in attenuating growth and viability of cancer cells with few 
observed side effects in humans when these agents are taken orally. The combination of 
multiple botanicals may prove to be more efficacious as compared with their use in 
isolation. These effects may be related to the fact that when bioactives are used in 
combination their synergy could reduce the concentration needed for effectiveness to one 
that is physiologic. For example, polyherbal mixtures can be quite effective in inhibiting 
cancer cell proliferation when individual herbal extracts have no effect (Figure II.1). 
Furthermore, in vitro studies demand concentrations (often in the 20-100 µM range) [30, 
90] that are several orders of magnitude higher than nM doses achievable in humans. The 
difference between the effects seen in vitro using micromolar concentrations when 
compared with the nanomolar concentrations measured in human, raises the issue of the 
translational relevance of some of the in vitro studies, which likely accounts for at least 
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part of the disappointing outcomes in clinical trials [100]. Tables I.2 and I.3 summarize 
 
Figure II.1 The effects of individual herbs versus their combination on cell 
proliferation. 
CWR22Rv1 cells were treated with individual herbal extracts (10.2 µg/ml ginger, 15.4 
µg/ml rosemary, 11.3 µg/ml turmeric, 4.1 µg/ml Chinese goldthread, 10.2 µg/ml holy 
basil, 8.2 µg/ml hu zhang, 4.1 µg/ml barberry, 10.2 µg/ml green tea, 2.0 µg/ml Baikal 
skullcap or a combination equivalent to amounts used individually (76 ug/ml) for 48 hr 
and cell viability was measured by MTT assay (see “Methods” section of the paper). For 
more details of the mixture see references 7-9. Treatment with individual herbal extracts 
did not significantly affect cell viability, whereas their combination significantly reduced 
cell viability. Data is presented as means±SD (n=8). Bars with an asterisk (*) are 
significantly different from the non-treated Control at p<0.05. 
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this point where the mean IC50 concentrations observed in a variety of cancer cell lines 
are 41 µM, 21 µM, >243 µM and 29 µM for the bioactives berberine, curcumin, ar-
turmerone and coptisine, respectively, while the serum/plasma concentrations in humans 
provided oral doses of curcumin are in the nanomolar range. With one exception, the 
serum/plasma levels of curcumin are <200 nM at doses as high as 12 g (Table I.3). 
Maintaining an individual bioactive in the presence of other bioactive compounds 
(originally derived from the food or extract of origin) may turn isolated compounds that 
have weak bioactivity to those that have substantially more activity at lower doses. This 
would make translation to humans more feasible. For instance, the World Cancer 
Research Fund/American Institute for Cancer Research reports that consumption of 
individual nutrients could in some instances result in vastly different outcomes when 
compared with their foods of origin [251]. This concept of the importance of the complex 
source versus isolated nutrients is echoed by the American Cancer Society [252]. 
Importantly, this concept can be equally applied to combinations of foods or botanicals. 
To investigate the synergistic action of botanicals, we used CWR22Rv1 and 
HEK293 cells. CWR22Rv1 cells are an in vitro model of castrate-resistant prostate 
cancer (PCa) [169] and complement our research investigating the effects of a mixture of 
bioactive botanicals on in vitro and in vivo models of castrate-resistant PCa [175, 176, 
182]. The HEK293 cell line is a transformed human embryonic kidney cell that is widely 
used as a tool for expression vectors [171]. In this case, HEK293 cells were transfected 
with a recombinant plasmid expressing a luciferase gene under the control of a 
multimerized NF-κB responsive-promoter stimulated with TNFα [253]. 
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  In Traditional Chinese Medicine [254], Chinese goldthread and turmeric are used 
in combination to treat a variety of diseases, among them cancer. Cancer has been 
explained as a combination of damp-heat and blood stasis where the anti-cancer effects of 
Chinese goldthread and turmeric can be explained as damp-heat removing [81, 90] and 
blood stasis improving [81], respectively. The use of Chinese goldthread and turmeric 
complement our previous studies involving a polyherbal mixture containing these two 
herbal extracts [175, 176, 182]. 
While Chinese goldthread (Coptis chinensis) has been tested in a number of 
cancers [85, 255-257], very little is known about its impact on PCa. Instead, berberine, 
the major bioactive phytochemical in Chinese goldthread (estimated to be ~6% [89, 258]) 
has been preferentially studied and has been found to inhibit cell growth at concentrations 
of 30 µM to 100 µM in androgen-dependent and androgen-independent PCa cells [44, 47, 
48]. A minor constituent in this herb is coptisine (ratio of berberine to coptisine is 
approximately 5:1) [258]; however, this compound and the potential synergy between 
these compounds has yet to be tested.  
Turmeric (Curcuma longa) is a plant commonly found in Asia from the ginger 
family. Like Chinese goldthread, extracts of turmeric are not typically used in studies; 
instead curcumin, one of its primary ingredients known for its anticancer properties, is 
the primary target of investigation [259, 260]. Curcumin is the major curcuminoid in 
turmeric at a level of ~5-6% [42, 261]. The molecular targets of curcumin are extensive 
(as reviewed elsewhere [259, 262]). For example, curcumin has been shown to modify 
those targets involved in inflammation, apoptosis, angiogenesis, metastasis and the 
expression of transcription factors, various receptors, growth factors and a variety of 
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protein kinases. However, curcumin inhibits androgen-dependent and androgen-
independent PCa cell growth at concentrations of 40 µM to 100 µM [263]. While the 
diversity of compounds in turmeric is extensive [42, 77], a less commonly studied one is 
ar-turmerone from the sesquiterpenes (ratio of curcumin to ar-turmerone in turmeric is 
approximately 4:1) [264, 265], with reported IC50 values in a variety of cancer cell lines 
of >243 µM [80, 105, 108, 113, 116]; however, ar-turmerone has not been studied in PCa. 
Similarly, the potential synergy between these compounds has yet to be tested. 
The objective of this study was to build upon the concept that the combination of 
bioactives in botanicals is far more effective than an individual bioactive in isolation. 
While this seems intuitive, a systematic approach yielding solid experimental evidence 
has yet to be fully explored. To address this issue, we determined if synergy could 
explain the enhanced effect of (a) the combination of herbs over isolated bioactives 
derived from those herbs, (b) the combination of bioactives over isolated bioactives 
derived from the same herb (companion compounds), (c) the combination of herbs over 
individual herbs, (d) the combination of bioactives from different herbs over the isolated 
bioactives, and (e) whether these synergistic effects on proliferation can apply at the 
molecular level. NF-κB expression was chosen as the molecular target because of its link 
in castrate-resistant PCa [266, 267] and because it has been previously identified as a 
target of bioactive phytonutrients and natural products [268, 269].  
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2.2 Materials and Methods 
2.2.1 Experimental design 
The experimental design for testing synergistic interactions is presented in Figure 
II.2. The comparisons made in this study included the combinations of herbs (inter-
interactions), comparison of the herb to its major bioactive (i.e., Chinese goldthread 
versus berberine and turmeric versus curcumin), combinations of bioactives from the 
same herb (intra-interaction) and combinations of bioactives from different herbs (inter-
interactions). 
2.2.2 Chemicals 
The herbal extracts of Chinese goldthread (Coptis chinensis) and turmeric 
(Curcuma longa) were provided by New Chapter (Brattleboro, VT). Fourier transform 
infrared spectroscopy was used to independently identify the raw materials and they were 
further verified by independent laboratories using a variety of analytical approaches (i.e., 
high performance and thin layer chromatographies and mass spectrometry) (as described 
previously) [176]. Quality control was determined by ranges of select bioactives, such as 
curcuminoids in turmeric and berberine in Chinese goldthread. Berberine (98% purity) 
was purchased from MP Biomedicals (Solon, OH), curcumin (98% purity) from Fischer 
Scientific (Pittsburgh, PA), coptisine (98% purity) from Quality Phytochemicals (Edison, 
NJ), and ar-turmerone (90% purity) from Sigma-Aldrich (St. Louis, MO). All substances 
were dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St. Louis, MO) to varied 
stock concentrations. RPMI 1640 cell culture media (Invitrogen, Grand Island, NY), 
supplemented with 0.5% fetal bovine serum (FBS, Invitrogen, Grand Island, NY) was 
used to dilute each stock solution to the required final concentrations. 
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Figure II.2 Experimental design. 
Comparisons were made between herbs and their major bioactives, among combinations 
of herbs (inter-interaction of herbs) and combinations of bioactives from the same herb 
(intra-interaction of isolated bioactives) or different herbs (inter-interactions of isolated 
bioactives). 
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2.2.3 Cell Culture 
For the experimental treatments, CWR22Rv1 cells (American Type Culture 
Collection, Rockville, MD), a human-derived castrate-resistant PCa line, were grown in 
RPMI 1640 media supplemented with 10% FBS under an atmosphere of 5% CO2 at 37°C. 
Prior to the experiments the level of FBS was reduced to 0.5%. HEK293 cells (ATCC, 
Rockville, MD), a human embryonic kidney cell line, were grown in DMEM media 
supplemented with 10%FBS under an atmosphere of 5% CO2 at 37°C. 
2.2.4 Cell Proliferation 
Cell growth and proliferation inhibition studies were performed using standard 96 
well plates and analyzed with the MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide] (Chalbiochem, Darmstadt, Germany) assay following the 
manufacturer’s instructions. CWR22Rv1 cells were plated at a density of 2×104 cells per 
well. After 24 hours, the FBS concentration in the cell culture media was reduced to 0.5% 
FBS and the cells were incubated overnight prior to the addition of the herbal extracts or 
phytochemicals. HEK293 cells were plated at a density of 1×10
4
 cells per well. After 24 
hours, the cells were incubated with herbal extracts or phytochemicals. After 48 hr 
incubation, cell viability and proliferation were measured via the MTT assay. Briefly, 
medium was replaced by 100 µl of 0.5 mg/ml MTT and cells were incubated for 4 hr at 
37°C. Intracellular formazan crystals were solubilized with 100 µl isopropanol/0.04 N 
HCl. Absorbance was read at 540 nm on a SpectraCount microplate photometer (Perkin 
Elmer Inc, Waltham, MA). 
2.2.5 Transfection and luciferase assay 
The multimerized NF- κB promoter luciferase vector has been described 
elsewhere [11]. Transient transfection of luciferase reporter constructs into HEK293 cells 
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was achieved using Lipofectamine
®
 2000 (Life technologies, Grand Island, NY) 
following manufacturer’s instructions. Briefly, HEK293 cells were plated at a density of 
1.5×10
4
 cells per well in 96 well plates. After 24 hr, 4 ng/well of plasmid was transfected 
with 0.32 μl/well Lipofectamine® 2000. After incubating overnight, transfection medium 
was removed and cells were incubated with herbal extracts or phytochemicals in 0.5% 
FBS supplemented DMEM medium for 1 hr. After incubation, HEK293 cells with 
luciferase reporter were stimulated by 5 ng/ml TNF-α for 4 hr.  Whole cell lysate was 
achieved by 20 μl passive lysis buffer (Promega, Madison, WI) and 10 μl was used for 
luciferase activity measurement by using the Luciferase Assay Reagent (Promega, 
Madison, WI). Luciferase activity was detected using the GloMax plate reading 
luminometer and normalized to total cellular protein concentration per well using the 
BCA assay (Thermo Scientific, Rockford, IL) following manufacturer’s instruction.  
2.2.6 Assessment of Synergistic, Additive or Antagonistic Effects of 
Combinations of Herbal Extracts and/or Phytochemicals 
To calculate the effects of compounds or herbs in combination, IC50 values were 
determined for each ingredient. For the experiments with the combination of herbal 
extracts, turmeric and Chinese goldthread were combined at a concentration equivalent to 
their IC50 values followed by serial dilutions to generate a dose response. For the 
experiments that combined individual bioactive phytochemicals from different herbal 
extracts (berberine and curcumin), they were combined at concentrations equivalent to 
their IC50 values, followed by serial dilutions to generate a dose response. For the 
experiments that combined individual bioactive phytochemicals from the same herbal 
extract (i.e., berberine and coptisine, curcumin and ar-turmerone), they were combined at 
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concentrations equivalent to their IC50 values or based on their relative ratios in their 
respective herbal extracts followed by serial dilutions to generate dose responses.  
Assessment of synergistic, additive or antagonistic effects of combinations was 
determined using the Chou-Talalay method [164]. This method is derived from mass-
action law principles as described in detail elsewhere [157]. The combination index (CI) 
and dose-reduction index (DRI) were used to differentiate synergy, antagonism and 
additive effects for combinations of components. CI and DRI were generated for all 
treatments with CompuSyn
®
 1.0 (Combo Syn, Paramus, NJ) according to the 
manufacturer’s instructions. CompuSyn® 1.0 software uses an algorithm based on the 
Chou-Talalay method to simulate the interaction of 2 or more compounds. Briefly, 
concentrations and corresponding effect levels for all data points were input to generate a 
complete report of analytical results. CI is a parameter that indicates whether the 
interaction of two compounds is synergistic, additive, or antagonistic [additive (CI = 1); 
synergistic (CI < 1); antagonistic (CI > 1)]. DRI is a parameter that indicates the degree 
to which the concentration of a compound can be reduced when used in combination with 
another compound to maintain an equivalent effect. The use of CI and DRI provide 
numerical assessments of not only whether there is synergy, but the extent of that synergy 
and synergy at particular doses [164]. 
2.2.7 Statistical analysis 
The results were presented as mean ± SEM and were analyzed by two-tailed 
student’s T-test. Differences were considered significant at p<0.05. 
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2.3 Results 
2.3.1 Cell proliferation 
Dose response curves were generated for all bioactives tested in each cell type. 
All the bioactives and their extracts of origin reduced cell proliferation in a dose 
dependent manner (Figure. II.3). IC50 values of bioactives were used, in part, to 
determine the synergistic effect between different bioactives. 
2.3.2 Comparisons of Chinese goldthread with berberine, and turmeric with 
curcumin on cell proliferation 
Dose-response curves were generated for Chinese goldthread, berberine, turmeric 
and curcumin and their effectiveness inhibiting cell proliferation were compared based on 
the relative amounts of the phytonutrients in the herbal extract (i.e., the amount of 
berberine in Chinese goldthread and the amount of curcumin in turmeric). Proliferation of 
CWR22Rv1cells and HEK293 cells was reduced in dose-dependent manners with 
Chinese goldthread and berberine (Figure. II.3). Following normalization based on the 
relative amount of berberine in Chinese goldthread, there was a shift to the left in the IC50 
value, from 30 µM for berberine to 19 µM in CWR22Rv1 cells and from 30 µM for 
berberine to 11 µM in HEK293 cells (Figure. II.3). Cell proliferation was also reduced in 
dose-dependent manners with turmeric and curcumin (Figure. II.3). Following 
normalization based on the relative amount of curcumin in turmeric, there was a shift to 
the left of the IC50 value from 22 µM for curcumin to 9.5 µM for turmeric in CWR22Rv1 
cells and from 11 µM for curcumin to 4 µM for turmeric in HEK293 cells (Figure. II.4). 
These results collectively infer that other compounds within the original herbal extracts 
(companion compounds) may be acting in concert (i.e., synergism) with each of the 
bioactive phytonutrients. To explore this possibility, we investigated the effects of  
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Figure II.3 The effects of berberine, coptisine, curcumin, ar-turmerone, Chinese 
goldthread and turmeric on cell proliferation. 
Dose-response curves for cell proliferation were generated with berberine, coptisine, 
curcumin, ar-turmerone using (A) CWR22Rv1 cells and (B) HEK293 cells. (C) Dose-
response curves for cell proliferation were also generated with the herbal extracts of 
Chinese goldthread and turmeric for both cell lines. IC50 values of bioactives and herb 
extracts were generated from these curves. 
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Figure II.4 The comparison of berberine and curcumin on cell proliferation 
compared to their herbal extracts of origin, Chinese goldthread and turmeric, 
respectively, in CWR22Rv1 cells and HEK293 cells. 
Following normalization based on the relative amount of berberine in Chinese goldthread 
and curcumin in turmeric, dose-response curves were compared between Chinese 
goldthread and berberine in (A) CWR22Rv1 cells and (C) HEK293 cells, and between 
turmeric and curcumin in (B) CWR22Rv1 cells and (D) HEK293 cells. Compared to 
individual compounds, herbal extracts had a more pronounced effect on reducing cell 
proliferation compared to their isolated bioactives (shifts in IC50 values to the left). 
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combining companion phytonutrients from Chinese goldthread (i.e., berberine with 
coptisine) and turmeric (i.e., curcumin with ar-turmerone). 
2.3.3 Intra-herbal comparisons of companion phytonutrients (berberine with 
coptisine, curcumin with ar-turmerone) on cell proliferation 
Berberine and coptisine are two bioactive phytonutrients found in Chinese 
goldthread (companion phytonutrients) and their synergy could help explain, in part, the 
enhanced effectiveness of Chinese goldthread when compared with berberine in isolation. 
Berberine and coptisine reduced the proliferation of CW22Rv1 cells in dose-dependent 
manners with IC50 values of 30 µM and 85 µM, respectively (Figure II.3). In a similar 
manner, the proliferation of HEK293 cells was reduced by berberine and coptisine with 
IC50 values of 30 µM and 70 µM, respectively (Figure II.3). To determine the effects on 
proliferation with the combination, cells were treated with berberine plus coptisine with 
serial dilutions starting with concentrations equivalent to their IC50 values (30 µM:85 µM 
for CWR22Rv1, 30 µM:70 µM for HEK293) and reducing these to nanomolar 
concentrations while maintaining the same ratio. The combination of berberine plus 
coptisine reduced cell proliferation in a dose-dependent manner and the minimum 
effective doses were determined for both single phytochemicals and their combinations 
(Tables II.1 and II.2). CI and DRI values were generated for minimum effective doses by 
CompuSyn® 1.0, respectively. The combination of berberine plus coptisine reduce the 
minimum effective doses from µM level to nM level in CWR22Rv1 cells (7.5 µM for 
berberine, 21 µM for coptisine, and 0.24 µM+0.66 µM for their combination) and was 
highly synergistic in inhibiting cell growth at this level (CI equal to 0.05), with the DRIs 
being 52 and 37 when combined at the lowest concentrations (0.24 µM+0.66 µM). This 
means the addition of berberine to coptisine or coptisine to berberine reduced the  
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Table II.1 Dose-effect relationships of berberine and coptisine (from Chinese 
goldthread), curcumin and ar-turmerone (from turmeric), Chinese goldthread and 
turmeric and their combinations using their IC50 values or using ratios 
corresponding to relative amounts in their native extracts on proliferation of 
CWR22Rv1 cells. 
Isolated 
compounds and 
combinations 
Minimum 
Effective 
Dose (µM)
a
 
IC50 
(µM) 
Combination 
Index (CI) 
Dose 
Reduction 
Index (DRI) 
Berberine 7.5 30   
Coptisine 21 85   
Ber + Cop 
(ratio = 1 : 2.8)
b
 
0.24 + 0.66  0.05 Berberine: 52 
Coptisine:  37 
Ber + Cop 
(ratio = 5 : 1)
c
 
0.47 + 0.09  0.16 Berberine:   7 
Coptisine:  15 
Curcumin 5.5 22   
ar-turmerone 9.4 150   
Cur + ar-tur 
(ratio = 1 : 6.8)
b
 
0.17 + 1.2  0.09 Curcumin:        
37 
ar-turmerone: 
16 
Cur + ar-tur 
(ratio = 4 : 1)
d
 
0.34 + 0.09  0.06 Curcumin:        
18 
ar-turmerone: 
187 
Berberine 7.5 30   
Curcumin 5.5 22   
Ber + Cur 
(ratio = 1.4 : 1)
b
 
0.24 + 0.17  0.16 Berberine: 24 
Curcumin:  24 
Isolated herbal 
extracts and 
combinations 
Minimum 
Effective 
Dose (µg/ml)
a
 
IC50 
(µg/ml) 
Combination 
Index (CI) 
Dose 
Reduction 
Index (DRI) 
Chinese 
Goldthread 
65 130 µg/ml   
Turmeric 35 65 µg/ml   
Chinese GT + 
Tur 
(ratio = 2 : 1)
b
 
1.10 + 0.51  0.14 Chinese GT: 52 
Turmeric:     52 
a
Concentration derived from the dose-response curves where growth inhibition was 
significantly inhibited (p<0.05). 
b
Ratio based on IC50 values. 
c
Ratio based on relative 
amounts in Chinese goldthread. 
d
Ratio based on relative amounts in turmeric.  
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Table II.2 Dose-effect relationships of berberine and coptisine (from Chinese 
goldthread), curcumin and ar-turmerone (from turmeric), Chinese goldthread and 
turmeric and their combinations using their IC50 values or using ratios 
corresponding to relative amounts in their native extracts on proliferation of 
HEK293 cells. 
Isolated 
compounds and 
combinations 
Minimum 
Effective 
Dose (µM)
a
 
IC50 
(µM) 
Combination 
Index (CI) 
Dose 
Reduction 
Index (DRI) 
Berberine 15 30   
Coptisine 18 70   
Ber + Cop 
(ratio = 1 : 2.3)
b
 
3.75 + 8.75  0.42 Berberine: 5.2 
Coptisine:  4.5 
Ber + Cop 
(ratio = 5 : 1)
c
 
1.88 + 0.38  0.10 Berberine:   11 
Coptisine:  109 
Curcumin 11 11   
ar-turmerone 200 400   
Cur + ar-tur 
(ratio = 1 : 36)
b
 
0.69 + 25  0.45 Curcumin:        
15 
ar-turmerone: 
2.6 
Cur + ar-tur 
(ratio = 4 : 1)
d
 
11 + 2.75  0.64 Curcumin:        
2.8 
ar-turmerone: 
1.4 
Berberine 15 30   
Curcumin 11 11   
Ber + Cur 
(ratio = 2.7 : 1)
b
 
3.75+1.83  0.32 Berberine: 5.3 
Curcumin:  7.5 
Isolated herbal 
extracts and 
combinations 
Minimum 
Effective 
Dose (µg/ml)
a
 
IC50 
(µg/ml) 
Combination 
Index (CI) 
Dose 
Reduction 
Index (DRI) 
Chinese 
Goldthread 
40 80 µg/ml   
Turmeric 30 40 µg/ml   
Chinese GT + 
Tur 
(ratio = 2 : 1)
b
 
10 + 3.75  0.29 Chinese GT: 
6.8 
Turmeric:     
6.8 
a
Concentration derived from the dose-response curves where growth inhibition was 
significantly inhibited (p<0.05). 
b
Ratio based on IC50 values. 
c
Ratio based on relative 
amounts in Chinese goldthread. 
d
Ratio based on relative amounts in turmeric.  
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effective doses 52 and 37 fold, respectively, compared with each alone. In a similar 
manner, the combination of berberine plus coptisine also reduced the minimum effective 
doses significantly in HEK293 cells (15 µM for berberine, 17.5 µM for coptisine, and 
3.75 µM+8.75 µM for combination) and was highly synergistic in inhibiting cell growth 
at this level (CI equal to 0.42 with the DRIs being 3.2 and 32). 
Curcumin and ar-turmerone (two bioactive phytonutrients found in turmeric) 
reduced the proliferation of CW22Rv1 cells in dose-dependent manners with IC50 values 
of 22 µM and 150 µM, respectively (Table II.1). In a similar manner, the proliferation of 
HEK293 cells was reduced by curcumin and ar-turmerone with IC50 values of 11 µM and 
200 µM, respectively (Table II.2). To determine the effects on proliferation with the 
combination, cells were treated with curcumin plus ar-turmerone with serial dilutions 
starting with concentrations equivalent to their IC50 values (22 µM:150 µM for 
CWR22Rv1, 11 µM:200 µM for HEK293) and reducing these to nanomolar 
concentrations while maintaining the same ratio (Tables II.1 and II.2). The dose-response 
curves with the combination of curcumin plus ar-turmerone reduced cell proliferation in 
a dose-dependent manner. The combination of curcumin plus ar-turmerone reduced the 
minimum effective doses in CWR22Rv1 cells (5.5 µM for curcumin, 9.4 µM for ar-
turmerone, and 0.17 µM +1.2 µM for their combination) and was highly synergistic in 
inhibiting cell growth at this level (CI equal to 0.09 with the DRIs being 37 and 16). In a 
similar manner, the combination of curcumin plus ar-turmerone also reduced the 
minimum effective doses significantly in HEK293 cells (11 µM for curcumin, 200 µM 
for ar-turmerone, 0.69 µM+25 µM for their combination) and was highly synergistic in 
inhibiting cell growth at this level (CI equal to 0.45 with the DRIs being 14 and 2.6).  
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While it is standard practice to use the ratio of the IC50 values to evaluate synergy, 
the ratio of these bioactive phytonutrients from their respective herbal extracts are 
different. For example, the ratio of berberine to coptisine in Chinese goldthread is ~5:1, 
and curcumin to ar-turmerone is ~4:1. As such, synergy was also assessed at more 
“natural” ratios (Tables II.1 and II.2). For CWR22Rv1 cells, the combination of berberine 
and coptisine was highly synergistic in inhibiting cell growth at minimum effective 
concentrations (0.469 µM+0.094 µM) where the CI was 0.16, respectively. The DRI 
values at these concentrations were 6.8 and 14.6 for berberine and coptisine, respectively. 
Similarly, using HEK293 cells, the combination of berberine and coptisine in a 5:1 ratio 
was highly synergistic in inhibiting cell growth in minimum effective concentrations 
(1.88 µM+0.38 µM) where the CI was 0.10, respectively. The DRI values at these 
concentrations were 11 and 109 for berberine and coptisine, respectively. 
Using CWR22Rv1 cells, the combination of curcumin plus ar-turmerone were 
also highly synergistic in inhibiting cell growth at concentrations as low as 0.344 
µM+0.086 µM, respectively (Table II.1), where the CI was 0.06. The DRI values at these 
concentrations were 17.6 and 187 for curcumin and ar-turmerone, respectively. Using 
HEK293 cells, the combination of curcumin and ar-turmerone was synergistic in 
inhibiting cell growth at minimum effective concentrations of 11 µM+2.75 µM, 
respectively, where the CI was 0.64 (Table II.2). The DRI values at these concentrations 
were 2.4 and 3.8 for curcumin and ar-turmerone, respectively. 
2.3.4 Inter-herbal comparison of the extracts of Chinese goldthread with 
turmeric on cell proliferation 
The extracts of Chinese goldthread and turmeric reduced the proliferation of 
CWR22Rv1 and HEK293 cells in dose-dependent manners (IC50 values for CWR22Rv1 
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cells were 130 µg/ml and 65 µg/ml, for HEK293 cells were 80 µg/ml and 30µg/ml, 
respectively) (Figure II.3). To determine the effects on proliferation with the combination, 
cells were treated with Chinese goldthread plus turmeric with serial dilutions starting 
with combined concentrations equivalent to their IC50 values (130 µg/ml:65 µg/ml for 
CWR22Rv1 cells and 80 µg/ml:30 µg/ml for HEK293 cells) and going as low as ≤1 
µg/ml (maintaining the same ratio). The combination of Chinese goldthread plus turmeric 
qualitatively reduced cell proliferation in a dose-dependent manner for both cell lines 
(Tables II.1 and II.2). CI and DRI values were generated at minimum effective 
concentrations. For CWR22Rv1 cells, the minimum effective concentration was more 
than 100 times lower than their respective IC50 values (1.103 µg/ml+0.508 µg/ml, 
respectively). The combination of Chinese goldthread and turmeric were highly 
synergistic in inhibiting cell growth at these doses, where the CI was 0.04, respectively. 
The DRI values at the minimum effective concentrations were 51.6 and 52.1 for Chinese 
goldthread and turmeric, respectively. Using HEK293 cells, the minimum effective 
concentrations were significantly reduced to 10 µg/ml+3.75 µg/ml. The combination was 
highly synergistic at these doses, where the CI was 0.29. The DRI values at the minimum 
effective concentrations were 6.8 and 6.8, respectively. 
2.3.5 Inter-herbal comparison of phytonutrients (berberine with curcumin) 
To explain, in part, the synergism between Chinese goldthread and turmeric, 
isolated bioactive compounds from each herb (i.e., berberine and curcumin) were 
evaluated for synergy. To determine the effects on proliferation with the combination, 
cells were treated with berberine plus curcumin with serial dilutions starting with 
concentrations equivalent to their IC50 values (30 µM:22 µM for CWR22Rv1 cells and 
30 µM:11 µM for HEK293 cells) and reducing these to nanomolar concentrations while 
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maintaining the same ratio. The combination of berberine plus curcumin reduced cell 
proliferation in a dose-dependent manner for both cell lines (Tables II.1 and II.2). CI and 
DRI values were generated for minimum effective concentrations. For CWR22Rv1 cells, 
the combination of berberine and curcumin was highly synergistic in inhibiting cell 
growth at these levels (CI equal to 0.08, respectively), with the DRIs being 23.5 and 23.7 
when combined at the minimum effective concentrations (0.235 µM+0.172 µM) (Table 
II.1).  Similar results were observed with HEK293 cells (Table II.2). The combination of 
berberine and curcumin was highly synergistic in inhibiting cell growth at these levels 
(CI equal to 0.32), with the DRIs being 5.3 and 7.5 when combined at the minimum 
effective concentrations (3.75 µM+1.38 µM). 
2.3.6 TNFα-stimulated NF-κB expression 
Dose response curves were generated for all bioactives and extracts tested in 
HEK293 cells. All the bioactives and their extracts of origin, except berberine and 
Chinese goldthread, reduced NF-κB expression in a dose dependent manner (Figure II.5). 
IC50 values of bioactives were used, in part, to determine the synergistic effect between 
different bioactives. 
2.3.7 Comparisons of turmeric with curcumin on TNFα-stimulated NF-κB 
expression 
Dose-response curves were generated for turmeric and curcumin and their 
effectiveness inhibiting NF-κB expression were compared based on the relative amounts 
of the phytonutrients in the herbal extract (i.e., the amount of curcumin in turmeric). NF-
κB expression was reduced in dose-dependent manners with turmeric and curcumin 
(Figure II.5). Following normalization based on the relative amount of curcumin in 
turmeric, there was a shift to the left in the IC50 value, from 20 µM for curcumin to 10  
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Figure II.5 The effects of berberine, coptisine, curcumin, ar-turmerone, Chinese 
goldthread and turmeric on inhibition of TNFα-stimulated NF-κB expression in 
HEK293 cells. 
Dose-response curves were generated with (A) berberine, coptisine, curcumin, ar-
turmerone) and (B) Chinese goldthread and turmeric. IC50 values of the bioactives and 
turmeric were generated from these curves.  
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µM (Figure II.6). These results collectively infer that companion compounds in turmeric 
may be acting synergistically with curcumin. To explore this possibility, we investigated 
the effects of combining the companion ar-turmerone with curcumin. 
2.3.8 Intra-herbal comparisons of companion phytonutrients (curcumin with ar-
turmerone) on TNFα-stimulated NF-κB expression 
Curcumin and ar-turmerone (two bioactive phytonutrients found in turmeric) 
reduced the NF-κB expression in dose-dependent manners with IC50 values of 20 µM and 
275 µM, respectively (Figure II.5). To determine the effects on NF-κB expression with 
the combination, cells were treated with curcumin plus ar-turmerone with serial dilutions 
starting with concentrations equivalent to their IC50 values (20 µM:275 µM) and reducing 
these to nanomolar concentrations while maintaining the same ratio (Table II.3). The 
dose-response curves with the combination of curcumin plus ar-turmerone reduced NF-
κB expression in a dose-dependent manner. The combination of curcumin plus ar-
turmerone reduced the minimum effective concentrations of 20 µM for curcumin and 275 
µM for ar-turmerone to 0.16 µM+2.15 µM for their combination, respectively (Table 
II.3). The combination was highly synergistic in inhibiting NF-κB expression (CI equal to 
0.01 with the DRIs being 109 and 311), In a similar manner, the combination of curcumin 
plus ar-turmerone in a ratio based on relative amounts in turmeric (ratio of 4:1; Table II.3) 
also reduced the minimum effective doses significantly from 20 µM for curcumin and 
275 µM for ar-turmerone to 0.63 µM+0.16 µM for their combination, respectively. This 
effect was also highly synergistic in inhibiting NF-κB expression at these concentrations 
(CI equal to 0.04 with the DRIs being 23 and 3563). 
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Figure II.6 The effects of curcumin and turmeric on inhibition of TNFα-stimulated 
NF-κB expression. 
HEK 293 cells were treated with serial dilutions of either curcumin or turmeric and 
inhibition of TNFα-stimulated NF-κB expression was determined. Following 
normalization based on the relative amount of curcumin in turmeric, dose-response 
curves were compared between turmeric. 
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Table II.3 Dose-effect relationships of curcumin and ar-turmerone (from turmeric), 
curcumin (from turmeric) and coptisine (from Chinese goldthread), and Chinese 
goldthread and turmeric and their combinations using their IC50 values or using 
ratios corresponding to relative amounts in their native extracts on NF-κB promoter 
activity using transfected HEK293 cells. 
Isolated 
compounds and 
combinations 
Minimum 
Effective 
Dose (µM)
a
 
IC50 
(µM) 
Combination 
Index (CI) 
Dose Reduction 
Index (DRI) 
Curcumin 20 20   
ar-turmerone 275 275   
Cur + ar-tur 
(ratio = 1 : 14)
b
 
0.16+2.15  0.01 Curcumin:      109 
ar-turmerone: 311 
 
Cur + ar-tur 
(ratio = 4 : 1)
c
 
0.63+0.16  0.04 Curcumin:        23 
ar-turmerone: 
3563 
Curcumin 20 20   
Coptisine 80 80   
Cur+Cop 
(Ratio=1:4)
b
 
0.31+1.25  0.03 Curcumin: 70 
Coptisine:  42 
Isolated herbal 
extracts and 
combinations 
Minimum 
Effective 
Dose 
(µg/ml)a 
IC50 
(µg/ml) 
Combination 
Index (CI) 
Dose Reduction 
Index (DRI) 
Chinese 
goldthread 
- -   
Turmeric 70 70   
Chinese 
goldthread 
+turmeric 
200+8.75  - - 
- 
a
Concentration derived from the dose-response curves where NF-κB expression was 
significantly inhibited (p<0.05). 
b
Ratio based on IC50 values. 
c
Ratio based on relative 
amounts in turmeric. Abbreviations: Cur, curcumin; ar-tur, ar-tumerone; Cop, coptisine; 
Chinese GT, Chinese Goldthread; Tur, turmeric. 
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2.3.9 Inter-herbal comparison of the extracts of Chinese goldthread with 
turmeric on TNFα-stimulated NF-κB expression 
The extract of Chinese goldthread did not reduce NF-κB expression using 
concentrations up to 400 µg/ml (Figure II.5B). In contrast, turmeric reduced the NF-κB 
expression in a dose-dependent manner (IC50 value was 70 µg/ml) (Figure II.5B). To 
determine the effects on NF-κB expression with the combination, cells were treated with 
200 µg/ml Chinese goldthread plus progressive dilutions of turmeric beginning at 70 
µg/ml. The combination of Chinese goldthread plus turmeric reduced the minimum 
effective dose of turmeric from 70 µg/ml to 8.75 µg/ml with the combination (Table II.3). 
CI and DRI values were not generated due to the lack of a dose-response curve for 
Chinese goldthread. 
2.3.10 Inter-herbal comparison of phytonutrients (coptisine with curcumin) on 
TNFα-stimulated NF-κB expression 
Berberine, just like Chinese goldthread, did not reduce NF-κB transcriptional 
activity using concentrations up to 100 µM (Figure II.5A). In an effort to explain, in part, 
the inter-herbal synergism between Chinese goldthread and turmeric, coptisine from 
Chinese goldthread and curcumin from turmeric were evaluated for synergy (Table II.3). 
To determine the effects on NF-κB expression with the combination, cells were treated 
with curcumin plus coptisine with serial dilutions from concentrations equivalent to their 
IC50 values (20 µM:80 µM) to nanomolar concentrations while maintaining the same 
ratio. The combination of curcumin plus coptisine reduced NF-κB expression in a dose-
dependent manner. CI and DRI values were generated for minimum effective 
concentrations. The combination of curcumin and coptisine was highly synergistic in 
inhibiting NF-κB expression at these levels, where the CI was equal to 0.03, and the DRIs 
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being 70 and 42 when combined at the minimum effective concentrations (0.31 µM+1.25 
µM) (Table II.3). 
2.4 Discussions 
It has been proposed that traditional medicines from various cultures (i.e., 
Traditional Chinese Medicine) provide effective remedies due to their combinations of 
herbals, but there is a challenge in establishing a rationale for their superior therapeutic 
value compared with using isolated bioactives [154] . There is growing evidence that the 
benefits of combinations of essential and non-essential nutritive lie in their synergy and 
multiple targets of action [133]. This concept is presented in several reviews describing 
the lack of concordance between observational studies of bioactives compared with the 
foods from which the bioactives are derived (i.e., the impact of β-carotene versus foods 
that contain β-carotene on the risk of lung cancer) [100, 133].  
The mechanisms of the anticancer effects of berberine, curcumin and their herbs 
from which they are derived have been extensively studied, where they have been shown 
to modulate cancer cells to induce cell-cycle arrest, cellular apoptosis and inhibition of 
cell invasion and metastasis. Multiple signaling pathways are known to be affected 
(including cyclin D, caspase-3, NF-κB, PI3 kinase, TNF-α, COX-2, MMP-9, etc.) and are 
well-documented [42, 81, 90, 93, 259, 260, 270-272]. Thus, it is not necessary for us to 
duplicate these mechanistic studies. The aim of this paper was not to revisit the 
established mechanisms of the anticancer effects of these bioactives, but to assess the 
synergistic effect between bioactives and compare them to the herbs from which they are 
derived.  
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It has been suggested that synergy of polyherbals is related to their multiple 
targets of action, their coordinated impact on bioavailability, and their collective ability to 
minimize/neutralize adverse side effects [154]. Furthermore, while many bioactives from 
botanicals have the same targets [273], it is not always clear whether the mechanisms 
modifying these targets are similar. Because of our ability to demonstrate the 
combinations used in this study function synergistically (and not additively), these data 
suggest while some mechanisms may overlap, others involve biological convergence 
(modifying a biological outcome, such as cell proliferation, via several pathways) and 
biochemical convergence (modifying a biochemical pathway, such as NF-κB expression, 
via several mechanisms). 
Also important is the concept that the combination of compounds could 
sufficiently lower the effective dose/concentration when compared with the individual 
compounds, and similarly, the ability of the combination of herbs to lower the effective 
dose/concentration when compared with individual herbs or individual bioactives derived 
from the herbs. If this effective dose/concentration can be sufficiently lowered, there is a 
better chance that it could have biological meaning, i.e., shifting the effective levels from 
micromolar to nanomolar concentrations. For most underivatized bioactive 
phytonutrients, their effective concentrations on cells in culture are typically between 20-
100 µM (see Table I.2) [30], while the total plasma/serum concentrations (derivatized 
and underivatized) are typically two to three orders of magnitude lower following oral 
dosing (see Tables I.2 and I.3) [137, 274, 275].  
Investigations in the chemopreventative effects of phytonutrients are not new, but 
confirming the concept that effectiveness of the botanicals from which these 
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phytonutrients are derived, particularly through dose-reduction, may be superior because 
the synergy of action has been poorly explored. To quantitate this kind of interaction, we 
used the Chou-Talalay method of analysis [157]. This method can differentiate between 
synergy, additive effects and antagonism of combinations of agents. It is based on the use 
of a constant ratio of components through a variety of concentrations (i.e., serial dilutions) 
while monitoring a single end point (in our case cell proliferation or promoter activation). 
This computerized model establishes the CI (combination index) to determine the type of 
interaction, and the DRI (dose-reduction index) represents the magnitude of the dose 
reduction as a result of the combination for a given dose.  
These data are typically generated using ratios of the IC50 values from dose-
response curves generated for each individual agent and are presented in each of the 
tables. Data can also be generated, and was presented in the tables, using concentrations 
that approach physiological relevance where cell growth was still significantly inhibited. 
The DRI is important at physiologically relevant concentrations (those plasma/serum 
concentrations following an oral dose) to establish potential therapeutic value. Because 
individual phytonutrients within the same botanical (what we refer to as “companion 
compounds”) exist in ratios that may be different from the IC50 values, we also ran a 
parallel set of experiments using those ratios for biological relevance. For example, the 
IC50 values for berberine and coptisine are 30 µM and 85 µM, respectively, for a ratio of 
1:2.8, but in Chinese goldthread these two compounds exist in a ratio closer to 5:1. The 
DRI can tell us to what extent one compound can enhance the effectiveness of another 
compound at a given ratio and dose compared with the compound alone [164].  
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This study systematically demonstrates that the enhanced effects of herbal 
extracts compared with individual bioactives found in those extracts may be explained by 
the synergy of action of the companion compounds found within that extract. When the 
extract of turmeric was compared with curcumin and the extract of Chinese goldthread 
compared with berberine, the dose response curves shifted to the left suggesting 
companion compounds within the extracts could be responsible for this shift by acting in 
synergy. This was confirmed by establishing the synergy (CI values <1) between 
companion bioactives from the same extract (i.e., curcumin plus ar-turmerone from 
turmeric, and berberine plus coptisine from Chinese goldthread).   
In addition, this study further supports the concept that the synergy observed by 
combining two different herbal extracts could, in part, be explained by their synergistic 
action and due, in part, to the synergistic action of the combination of individual 
bioactives uniquely derived from these different sources. This is easily illustrated by 
comparing our previous results with our current results on the ability of Chinese 
goldthread and turmeric to inhibit proliferation of CWR22Rv1 cells (Figure II.1). 
Chinese goldthread and turmeric, when isolated from a polyherbal mixture, were unable 
to inhibit cell proliferation at doses of 4.1 μg/ml and 11.3 μg/ml, respectively, while our 
current data demonstrates inhibition of proliferation was observed at doses as low as 1.1 
μg/ml and 0.5 μg/ml, respectively, when used in combination (Table II.3). It is believed 
that this synergistic effect is due, in part, to the combinations of bioactives unique to each 
of the extracts. When berberine (from Chinese goldthread) was combined with curcumin 
(from turmeric), the CI value demonstrated strong synergism. This supports the concept 
of improved effectiveness with targeted combinations of botanicals. 
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Our previous studies investigated the mechanisms of a polyherbal mixture 
containing Chinese goldthread and turmeric on the inhibition of castrate-resistant PCa in 
vitro and in vivo [175, 176, 182]. These inhibitory effects also included mechanisms 
involving TNFα-induced cell proliferation (Figure II.7). TNFα signals through NF-κB. 
As a follow-up, this study helps to better define the actions of two of the components in 
the polyherbal mixture, Chinese goldthread and turmeric, on this signaling pathway. 
Turmeric and curcumin inhibited NF-κB promoter activity, but Chinese goldthread and 
berberine were ineffective. Similar to our results, curcumin has been reported by others to 
inhibit NF-κB expression at similar concentrations observed in this study (~20 µM) [276-
281]. In contrast, Chinese goldthread and berberine did not inhibit NF-κB expression in 
this study, and others report similar results with berberine [282, 283]. Interestingly, 
coptisine, a component of Chinese goldthread, inhibited NF-κB expression, but these 
levels were much higher (IC50 =70 µM) than what could be achieved as a component of 
Chinese Goldthread, partially explaining why Chinese goldthread was ineffective. 
Interestingly, when curcumin was used in combination with the least active bioactives 
(i.e., coptisine and ar-turmerone), curcumin enhanced their effectiveness 32 and 3563 
fold, respectively. In addition, an ineffective Chinese goldthread lowered the minimum 
effective dose of turmeric 8 fold (a CI value could not be determined due to the lack of a 
dose response with Chinese goldthread).  
Importantly, these data suggest that even when bioactives appear to have little or 
no activity, they may still act synergistically with other bioactives when used in 
combination, underscoring the concepts of biological and biochemical convergence. In 
addition, our data demonstrate that these actions of synergy may be concentration  
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Figure II.7 Combination of herbal extracts may inhibit NF-κB in CWR22Rv1 cells. 
CWR22Rv1 cells were treated with a combination of herbal extracts (10.2 µg/ml ginger, 
15.4 µg/ml rosemary, 11.3 µg/ml turmeric, 4.1 µg/ml Chinese goldthread, 10.2 µg/ml 
holy basil, 8.2 µg/ml hu zhang, 4.1 µg/ml barberry, 10.2 µg/ml green tea, 2.0 µg/ml 
baikal skullcap with increasing combined concentrations (0, 15, 30, 38, 57, 76 ug/ml) 
with or without TNF-α (10 ng/ml) for 0, 24, 48, 72, and 96 hr. For more details of the 
herbal mixture see references 7-9. Cell viability was measured by MTT assay (see 
“Methods” section of the paper). TNF-α had a progressive effect on cell proliferation 
over time and this effect was attenuated in the presence of herbal mixture in a dose-
dependent manner. Data is presented as means±SD (n=8). 
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dependent. The use of concentrations higher than the IC50 values (i.e., IC90) for the 
combinations can act in a synergistic manner; however, many times this is not the case. 
In many instances, the CI values are >1 (antagonism) at concentrations higher than the 
IC50 value, but <1 (synergy) for concentrations lower than the IC50, (see Table II.4), 
underscoring the importance of concentrations used in studies. 
2.5 Conclusions 
In summary, most of today’s cancers are influenced by our environment, 
particularly by the botanicals we eat (i.e., herbs, fruits, vegetables). The major source of 
bioactive phytonutrients is from these foods. To understand the impact of their 
consumption, our objective was to investigate the concept that the combination of 
bioactives in botanicals is potentially far more effective than an individual bioactive in 
isolation. Our data is proof-of-principle that combinations of companion bioactives from 
the same source and bioactives from different sources act synergistically, providing some 
evidence that combinations found in botanicals (and foods) have advantages over isolated 
bioactives. Even compounds with poor efficacy can become more biologically active in 
the presence of companion compounds. These advantages translate into effective doses 
those are more physiologic. 
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Table II.4 Dose-effect relationships of Chinese goldthread, turmeric, berberine, coptisine, curcumin and ar-turmerone and 
their combinations on proliferation of CWR22Rv1 and HEK293 cells and NF-κB Promoter Activity. 
Compounds / 
combinations 
Dm 
(µM) 
m r CI 
IC25 
CI 
IC50 
CI 
IC75 
CI 
IC90 
DRI- 
IC25 
DRI- 
IC50 
DRI- 
IC75 
DRI- 
IC90 
DRI- 
IC25 
DRI- 
IC50 
DRI- 
IC75 
DRI- 
IC90 
Inhibition of Proliferation using CWR22Rv1 Cells  Ber Ber Ber Ber Cop Cop Cop Cop 
Berberine 23.1 1.7 0.9             
Coptisine 96.7 0.8 0.9             
Ber:Cop (1: 2.8)
a
 27.2 0.6 0.8 0.2 0.5 1.5 4.7 11.8 3.3 0.9 0.1 8.4 4.8 2.7 1.6 
Ber:Cop (5: 1)
b
 25.3 1.2 0.9 0.8 0.9 1.2 1.6 1.4 1.1 0.8 0.6 14.5 22.9 36.3 57.3 
Inhibition of Proliferation using CWR22Rv1 Cells  Cur Cur Cur Cur ar-T ar-T ar-T ar-T 
Curcumin 11.4 2.1 0.9             
ar-turmerone 328.3 0.4 0.9             
Cur:arT (1: 6.8)
a
 13.8 1.2 0.7 0.3 0.2 0.2 0.4 10.0 6.4 4.1 2.7 6.0 27.3 124 564 
Cur:arT (4: 1)
b
 4.4 1.0 0.8 0.2 0.3 0.6 1.1 6.1 3.2 1.7 0.9 99.4 371 1386 5173 
Inhibition of Proliferation using CWR22Rv1 Cells  Ber Ber Ber Ber Cur Cur Cur Cur 
Berberine 23.1 1.7 0.9             
Curcumin 11.4 2.1 0.9             
Ber:Cur (1.4: 1)
a
 13.8 1.2 0.7 0.5 0.6 0.7 0.9 4.8 4.3 3.9 3.5 3.9 2.9 2.1 1.6 
Inhibition of Proliferation using CWR22Rv1 Cells  CG CG CG CG Tur Tur Tur Tur 
Chinese goldthread 106 1.6 0.9             
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Table II.4. Continued 
Compounds / 
combinations 
Dm 
(µM) 
m r CI 
IC25 
CI 
IC50 
CI 
IC75 
CI 
IC90 
DRI- 
IC25 
DRI- 
IC50 
DRI- 
IC75 
DRI- 
IC90 
DRI- 
IC25 
DRI- 
IC50 
DRI- 
IC75 
DRI- 
IC90 
Turmeric 49.6 1.8 0.8             
Chinese GT: Tur (2: 1)
a
 87.5 0.6 0.8 0.3 1.1 3.7 12 5.7 1.8 0.6 0.2 5.8 1.7 0.5 0.2 
Inhibition of Proliferation using HEK293 Cells  Ber Ber Ber Ber Cop Cop Cop Cop 
Berberine 42.9 2.6 0.9             
Coptisine 81.9 2.8 0.9             
Ber:Cop (1: 2.3)
a
 51.2 2.0 0.9 0.7 0.8 0.9 1.0 3.2 2.8 2.5 2.2 2.7 2.3 2.0 1.7 
Ber:Cop (5: 1)
b
 33.3 1.0 0.9 0.3 0.7 1.5 3.0 3.2 1.5 0.8 0.4 31.3 14.8 7.0 3.3 
Inhibition of Proliferation using HEK2931 Cells  Cur Cur Cur Cur ar-T ar-T ar-T ar-T 
Curcumin 17.3 3.2 0.9             
ar-turmerone 400.6 1.0 0.9             
Cur:arT (1: 6.8)
a
 100.3 1.3 0.9 0.4 0.4 0.4 0.6 10.6 6.4 4.0 2.4 3.1 4.1 5.5 2.4 
Cur:arT (4: 1)
b
 11.1 1.5 0.8 0.4 0.5 0.8 1.1 2.9 1.9 1.3 0.9 122 180 267 395 
Inhibition of Proliferation using HEK2931 Cells  Ber Ber Ber Ber Cur Cur Cur Cur 
Berberine 37.8 2.6 0.9             
Curcumin 17.2 3.2 0.9             
Ber:Cur (1.4: 1)
a
 18.0 1.9 0.9 0.5 0.6 0.8 0.9 3.3 2.9 2.5 2.1 4.5 3.6 2.8 2.2 
Inhibition of Proliferation using HEK2931 Cells  Ber Ber Ber Ber Cur Cur Cur Cur 
86 
 
Table II.4. Continued 
Compounds / 
combinations 
Dm 
(µM) 
m r CI 
IC25 
CI 
IC50 
CI 
IC75 
CI 
IC90 
DRI- 
IC25 
DRI- 
IC50 
DRI- 
IC75 
DRI- 
IC90 
DRI- 
IC25 
DRI- 
IC50 
DRI- 
IC75 
DRI- 
IC90 
Chinese goldthread 152 2.3 0.9             
Turmeric 49.3 2.9 0.8             
Chinese GT: Tur (2: 1)
a
 73.7 2.6 0.9 0.8 0.8 0.8 0.8 2.7 2.8 3.0 3.1 2.6 2.5 2.4 2.3 
NF-κB Promoter Activity using Transfected HEK293 Cells  CG CG CG CG Tur Tur Tur Tur 
Curcumin 35.0 1.3 0.5             
ar-turmerone 1418 1.3 0.5             
Cur:arT (1: 14)
a
 - - - - - - - - - - - - - - - 
Cur:arT (4: 1)
b
 43 0.8 0.4 0.6 0.9 1.7 2.9 1.8 1.0 0.6 0.3 273 166 101 61 
NF-κB Promoter Activity using Transfected HEK293 Cells  Cur Cur Cur Cur Cop Cop Cop Cop 
Curcumin 35.0 1.3 0.5             
Coptisine 90.3 1.1 0.6             
Cur: Cop (1: 4)
a
 16.2 0.7 0.8 0.1 0.2 0.4 0.7 20.5 10.8 5.7 3.0 11.6 7.0 4.2 2.5 
Dm: median-effect dose (concentration which inhibits cell growth by 50%). m: shape of the dose-effect curves, where m=1, hyperbolic; 
m>1, sigmoidal; and m<1, flat sigmoidal, respectively. r: linear correlation coefficient of the median-effect plot (indicates conformity 
of data). 
a
Ratio based on IC50 values. 
b
Ratio based on relative amounts in Chinese goldthread.  
Abbreviations: ar-T, ar-turmerone; Ber, berberine; CG, Chinese goldthread; CI, combination index; Cop, coptisine; Cur: curcumin; 
DRI, dose reduction index. 
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CHAPTER III  
ZYFLAMEND, A POLYHERBAL MIXTURE, INHIBITS 
LIPOGENSIS AND MTORC1 SIGNALING VIA ACTIVATION OF 
AMPK 
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Abstract 
 An extensive body of literature demonstrates that Zyflamend, a polyherbal 
mixture inhibits tumor growth at human doses. This complex mixture has been show anti-
prostate cancer (PCa) effects via multiple mechanisms. Reprogramming of metabolic 
pathways is a common feature of castrate resistant PCa (CRPC). Our preliminary data 
showed that Zyflamend regulated fatty acid metabolism by inhibiting synthesis and 
enhancing oxidation in CRPC cells, suggesting AMP-activated protein kinase (AMPK), 
the master energy sensor of cells, as a potential target. The objective of this study was to 
determine if the growth inhibitory effects of Zyflamend toward CRPC growth involves 
regulation of AMPK and downstream signaling. In castrate resistant PCa cells, 
Zyflamend activated AMPK, and in turn, regulated known downstream targets of AMPK, 
such as mammalian target of rapamycin complex 1 (mTORC1) and the phosphorylation 
of acetyl CoA carboxylase (ACC). The AMPK pathway regulatory effects and anti-
proliferative effects of Zyflamend could be mimicked by AMPK activation and 
attenuated by AMPK inhibition. Thus, we concluded that AMPK activation contributes to 
the anti-PCa effect of Zyflamend.  These novel results, along with those published 
previously, provide a more complete picture of how this polyherbal mixture may 
complement conventional treatments based on its multiple mechanisms of action.  
 
3.1 Introduction 
The National Center for Complementary and Alternative Medicine (NCCAM) 
defines complementary medicine as “using a non-mainstream approach together with 
conventional medicine” in the treatment of a condition or disease 
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(http://nccam.nih.gov/health/whatiscam).  It has been estimated that as much as 25% of 
individuals diagnosed with prostate cancer use some form of complementary therapy 
[284], with Zyflamend being among the choices [285].  
Zyflamend® (New Chapter, Brattleboro, VT) is a blend of 10 herbal extracts 
(ginger, rosemary, turmeric, Chinese goldthread, holy basil, hu zhang, barberry, oregano, 
green tea and basil skullcap) formulated based on their antioxidant and potentially anti-
inflammatory properties. To date, there have been 14 research articles investigating the 
anti-cancer effects of this blend, covering in vitro, preclinical and clinical studies 
involving the prostate, bone, skin, kidney, breast and pancreas [175, 176, 179-189, 250], 
with prostate being the predominant focus. It has been reported that a number of its 
constituents act synergistically such that physiological doses are possible [286] and 
multiple mechanisms of action have been linked in a variety of cancer cell lines by down 
regulating the androgen receptor [175, 176, 184], insulin-like growth factor-1R [176, 
182], class I and II HDACs [175, 176], COX-1 and COX-2 activities [181, 186, 189], 12-
LOX and Rb protein phosphorylation [183], and the up regulation of tumor suppressor 
genes such as p21 and p27 [175, 181]. Zyflamend has also been shown to modulate NF-
κB activation [185, 189], iNOS [186], apoptotic pathways [186, 188, 189], and aryl 
hydrocarbon receptor expression [250]. It is believed that it is the combination of 
bioactives that accounts for modulation of multiple pathways at relatively low doses (as 
described in references [176, 286]).  
AMPK is a master energy sensor in cells and responds to changes in the ratio of 
AMP:ATP such that when this ratio increases it responds by increasing ATP-generating 
pathways (i.e., β-oxidation) and concomitantly decreasing anabolic pathways such as 
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lipogenesis and protein synthesis [235]. Upregulation of AMPK activity inhibits acetyl 
CoA carboxylase (ACC) activity and down regulates the expression of fatty acid synthase 
(FASN) and the transcription factor sterol regulatory element binding protein-1c 
(SREBP-1c), key regulators of lipogenesis. AMPK also targets mTORC1, a complex of 
proteins comprised of mammalian target of rapamycin (mTOR), regulatory associated 
protein of mTOR (raptor), GβL (also known as mLST8) and PRAS40 [208]. This 
complex promotes protein synthesis and is negatively regulated by AMPK in part via the 
phosphorylation of raptor. Raptor acts as a scaffolding protein for downstream targets of 
the mTOR complex such as ribosomal S6 kinase (S6K) [208]. Recently, AMPK has been 
shown to be a potentially important target in the treatment of prostate cancer [237, 238, 
244-246].  
Recent research using Zyflamend in androgen dependent and castrate-resistant 
prostate cancer cell lines suggest multiple pathways may be involved in its synergistic 
mechanism of action [175, 176, 286]. Preliminary evidence from our laboratory 
demonstrating that Zyflamend down regulates SREBP-1c and FASN transcription and 
increases fatty acid oxidation suggests it may be regulating AMPK, a new discovery 
related to this blend of bioactives. Therefore, the objective of this study was to determine 
if Zyflamend could modulate AMPK activation and its downstream targets, biomarkers 
of fatty acid synthesis and mTORC1 signaling. These novel results, along with those 
published previously, can provide a more complete picture as to how blends of natural 
products may complement conventional treatments as a result of multiple mechanisms of 
action.  
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3.2 Materials and Methods 
3.2.1 Zyflamend 
Zyflamend® (New Chapter, Brattleboro, VT) is derived from the extracts of ten 
different commonly consumed herbs (w/w): holy basil (Ocimum sanctum 12.8%), 
turmeric (Curcuma longa 14.1%), ginger (Zingiber officinale 12.8%), green tea 
(Camellia sinensis 12.8%), rosemary (Rosmarinus officinalis 19.2%), hu zhang 
(Polygonum cuspidatum 10.2%), barberry (Berberis vulgaris 5.1%), oregano (Origanum 
vulgare 5.1%), baikal skullcap (Scutellaria baicalensis 2.5%), and Chinese goldthread 
(Coptis chinensis 5.1%).  Detailed description and characterization of the preparation of 
Zyflamend and quality assurance of the mixture has been described previously in detail 
[176]. 
3.2.2 Cell Culture 
Human prostate cancer cell lines, CWR22Rv1 and PC3 cells (American Type 
Culture Collection, Rockville, MD), were initially grown in RPMI 1640 media 
supplemented with 10% fetal bovine serum (FBS) under an atmosphere of 5% CO2 at 
37°C. For the experimental treatment, CWR22Rv1 and PC3 cells were then cultured in 
RPMI 1640 supplemented with 0.5% FBS containing 200 µg/mL Zyflamend 
reconstituted in dimethyl sulfoxide (DMSO) for cell proliferation assay, mRNA 
extraction, protein isolation and acetyl-CoA measurement. This dose was based on the 
dose responses generated in our laboratory, and in part, based on the maximum reported 
plasma concentrations of one of its major constituents, curcumin (~2 µM) [75, 175]. FBS 
at a concentration of 0.5% represents an androgen depleted environment [182]. Dose 
response curves and time course experiments were performed previously [175]. HEK293 
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cells (American Type Culture Collection, Rockville, MD) were grown in DMEM media 
supplemented with 10% FBS under an atmosphere of 5% CO2 at 37°C.  
3.2.3 Cell Proliferation 
Cell growth and proliferation inhibition studies were performed using standard 96 
well plates and analyzed with the MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide] (Chalbiochem, Darmstadt, Germany) assay following the 
manufacturer’s instructions. CWR22Rv1 cells were plated at a density of 2×104 cells per 
well. After 24 hr, the FBS concentration in the cell culture media was reduced to 0.5% 
FBS and the cells were incubated overnight prior to the addition of the Zyflamend (200 
μg/mL), AICAR (100 μM), Compound C (5 μM) or recombined adenovirus. After 48 hr 
incubation, cell viability and proliferation were measured via the MTT assay. Briefly, 
medium was replaced by 100 µl of 0.5 mg/ml MTT and cells were incubated for 4 hr at 
37°C. Intracellular formation crystals were solubilized with 100 µl isopropanol/0.04 N 
HCl. Absorbance was read at 540 nm on a SpectraCount microplate photometer (Perkin 
Elmer Inc, Waltham, MA). 
3.2.4 Down regulation of AMPKα1/2 by small interfering RNA 
CWR22Rv1 cells (2×10
5
 cells per well in 6-well plates, in transfection medium 
(sc-36868, Santa Cruz Biotechnology, Dallas, TX) were transfected with 80 pmols of 
siRNA for AMPKα1/2 (sc-29673, Santa Cruz Biotechnology, Dallas, TX) and a 
scrambled control siRNA (Control siRNA-A, sc-37007, Santa Cruz Biotechnology, 
Dallas, TX) using transfection reagent (sc-29528, Santa Cruz Biotechnology, Dallas, TX) 
as described by the manufacturer. Six hr post transfection cells were cultured with RPMI 
1640 media containing 10% FBS overnight. After recovery, media was replaced with 
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0.5% FBS media containing vehicle or Zyflamend (200 μg/mL) for 30 min at 37°C. The 
total protein was harvested for Western blot.  
3.2.5 Western blotting 
Cells were lysed in RIPA cell lysis buffer (Cell Signaling Technology, Danver, 
MA). Protein quantification was performed using BCA protein assay kit (Pierce 
Biotechnology, Rockford, IL). Equal amount of protein (20 µg) were fractioned by 8% 
SDS-PAGE and transferred to a polyvinylidine diflouride (PVDF) membrane by 
electroblotting. Membranes were blocked by 5% bovine serum albumin (BSA) (Santa 
Cruz Biotechnology, Dallas, TX) in 0.1% Tris-buffered saline (TBS) with 0.1% of 
Tween-20 for 1 hr at room temperature and incubated in TBST containing primary 
antibodies overnight at 4°C. Membranes were incubated with anti-mouse or anti-rabbit 
secondary antibody conjugate with horseradish peroxidase (HRP) (Cell Signaling 
Technology, Danver, MA). Protein expression was detected with Pierce ECL Western 
Blotting detection system and membranes were exposed to Hyperfilm Film (GE 
Healthcare, Piscataway, NJ) Antibodies of p-AMPKα (p172), AMPKα, p-ACC, ACC, p-
Raptor, Raptor, GβL, p-S6K, S6K (Cell Signaling Technology, Danver, MA) were used 
to detect target protein level. β-actin (Santa Cruz Biotechnology, Dallas, TX) was used as 
the control. 
3.2.6 Acetyl-Coenzyme A assay 
Acetyl-CoA was assayed using an acetyl-coenzyme A assay kit (Sigma-Aldrich, 
St. Louis, MO) according to the manufacturer’s instructions. The number of CWR22Rv1 
cells was counted after trypsinization and collection. Cells were homogenized in 400 µL 
acetyol CoA assay buffer and samples were deproteinized by adding 800 µL ice-cold 8% 
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perchloric acid (PCA). The resulting supernatant was neutralized by adding 3M KHCO3.  
Standards were quantified on a 0.2-1 nmol scale and 50 µL of sample was added to each 
well. The plate was read on a GloMax® Microplate Reader (Promega, Madison, WI) and 
results were normalized to cell number.  
3.2.7 Construction of recombinant adenovirus 
Plasmids containing cDNA of constitutively activated AMPKα1 or AMPKα2 
subunits were provided by Dr. Jian Yang (University of Alabama). AMPK cDNA was 
inserted to pACCMV plasmid and cotransfected with pJM17 into HEK293 cells by 
Lipofectamine 2000™ transfection reagent (Invitrogen, Carlsbad, CA) following the 
manufacturer’s instruction. Recombinant virus termed ad-CMV-ampkα1/α2 were 
produced and purified. Virus containing the bacterial β-galactosidase gene (ad-CMV-
βGal) was provided by Dr. Guoxun Chen (University of Tennessee-Knoxville) and used 
as control. Overexpression was verified by western blot.  
3.2.8 RNA isolation and quantitative Real Time-PCR 
Total RNA was isolated from CW22Rv1 cells using Trizol® reagent (Invitrogen, 
Carlsbad, CA) following the manufacturer’s instructions. Contaminating DNA was 
removed from RNA samples using Turbo DNA free
TM
 kit (Ambion, Austin, TX). 
Concentration of total RNA was measured using NanoDrop 1000
TM
 (Thermo Scientific, 
Wilmintion, DE) Complementary DNA (cDNA) was reverse-transcripted from RNA 
samples using TaqMan® reagent kit (Applied Biosystems, Carlsbad, CA) following the 
manufacturer’s instructions. Briefly, RNA (2 µg) was mixed with MultiScribeTM Reverse 
Transcriptase, RNase Inhibitor, dNTP Mixture, random hexamers, RT buffer, MgCl2 
solution and incubated 10 min at 25°C, 30 min at 48°C, 5 min at 95°C and then stored at 
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4 °C. cDNA samples were used for quantitative RT-PCR using ABI Prism® 7300 Real-
Time PCR System (Applied Biosystems, Carlsbad, CA). cDNA (0.7 µl) was used as a 
template for RT-PCR with 2.5 µM primer sets. PCR reactions were performed with 
standard thermocycle program: 1 min at 94°C, followed by 40 cycles of (15 sec at 94°C; 
30 sec at 50°C; 2 min at 72°C) followed by 5 min at 72°C. Each sample was in triplicated 
and normalized with 36B4. Primers for RT-PCR are listed below: 
SREBP1c, F: 5’-GCCATGGATTGCACTTT-3’, R: 5’-CAAGAGAGGAGCTCAATG-3’ 
FASN, F: 5’-CGCTCGGCATGGCTATCT-3’, R: 5’-CTCGTTGAAGAACGCATCCA-3’ 
36B4, F: 5’-TGCATCAGTACCCCATTCTATCA-3’, R: 5’-
AAGGTGTAATCCGTCTCCACAGA-3’. The relative amounts of all mRNAs were 
calculated using the comparative CT method as previously described with 36B4 as the 
invariant control [175].  
3.2.9 Extracellular Flux Analysis 
The rate of change of dissolved oxygen surrounding the monolayer of 
CWR22Rv1 cells was measured by XF24 Flux Analyzer (Seahorse Bioscience) following 
the manufacture’s protocol. Briefly, all assays were conducted using a seeding density of 
60,000 cells/well in 500 µL of RPMI 1640 (10% FBS) in a ploy-D-lysine-coated XF24-
will microplate (Seahorse Bioscience, Billerica, MA). After culturing cells in CO2 
incubator for 24 hr, cell medium was changed to Krebs-Henseleit Buffer (KHB, 111 mM 
NaCl, 4.7 mM KCl, 1.25 mM CaCl2, 2mM MgSO4, 1.2 mM NaH2PO4, PH 7.2) 
supplemented with 2.5 mM glucose, 0.5 mM carnitine and 25mM HEPES and incubate in 
37°C non-CO2 incubator for 1 hr. Then assays were placed in the analyzer and the 
oxygen consumption rate (OCR) could be detected by the fluorescent probes that contain 
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oxygen sensors. Each measure cycle contain mix and analysts for 3 min, quiescent for 2 
min and acquisition for 3 min. In this study, Zyflamend (200 µg/mL) or the controls 
(DMSO, Olive oil and AICAR) were injected first and OCR was measured for 3 cycles; 
BSA-Palmitate or BSA (87.5 µL, Seahorse Bioscience) were injected secondly and OCR 
was collected for 6 cycles; Etomoxir was injected thirdly and OCR was collected for 3 
cycles.  
3.2.10 Statistical analysis 
The results were presented as mean ± SD. For two group comparisons, the data 
was analyzed by two-tailed Student’s T-test. For multiple comparisons, the results were 
analyzed by an ANOVA followed by Tukey’s post hoc analysis when appropriate. 
Differences were considered significant at p<0.05. 
3.3 Results 
3.3.1 Zyflamend inhibited de novo fatty acid synthesis in CWR22Rv1 cells 
In preliminary experiments using CWR22Rv1 cells, Zyflamend treatment (24 hr) 
significantly decreased mRNA levels of SREBP-1c, the major transcriptional regulator of 
enzymes in lipogenic pathway by ~60% (Figure III.1A). It also decreased mRNA level of 
fatty acid synthase (FASN) by ~ 50% (Figure III.1A). Consistently, protein level of 
FASN was decreased by about 10% (Figure III.1B).  
3.3.2 Zyflamend increased fatty acid oxidation in CWR22Rv1 cells 
De novo lipogenesis is a necessary component in mediating cellular proliferation in 
cancer cells [287], one that is in opposition with fatty acid oxidation.  Because fatty acid 
synthesis, in part, regulates fatty acid oxidation, we determined if cellular β-oxidation  
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Figure III.1 Regulation of SREBP-1c and FASN expression by Zyflamend in 
CWR22Rv1 cells. 
(A) mRNA levels of SREBP1c and FASN from CWR22Rv1 cells treated in the presence 
or absence of Zyflamend (200 µg/ml). Data is presented as mean±SD, n=3. Group 
comparisons, Zyflamend versus control,* p<0.05.  (B) Western blot for FASN from 
CWR22Rv1 cells treated in the presence or absence of Zyflamend (200 µg/ml).   
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was increased in the presence of Zyflamend. CWR22Rv1 cells were treated in the 
presence or absence of Zyflamend using a Seahorse FX24 analyzer. Zyflamend increased 
fatty acid oxidation 6 fold as compared with control (olive oil) (Figure III.2A). As a 
positive control, we treated CWR22Rv1 cells with and without AICAR, which is known 
to activate AMPK, thus stimulating fatty acid oxidation. AICAR treatment increased fatty 
acid oxidation 4 fold compared to control (DMSO) (Figure III.2B).   
3.3.3 Zyflamend regulates AMPK phosphorylation in CWR22Rv1 and PC3 
prostate cancer cell lines 
In CWR22Rv1 cells, phosphorylation of AMPKα (T172) was increased by 
Zyflamend (200 µg/ml) ~3.5 fold after 30 min treatment (Figure III.3A, B). Similarly, 
Zyflamend increased phosphorylation of AMPKα (T172) by ~2 fold in PC3 cells. (Figure 
III.3C, D). 
3.3.4 Zyflamend regulates downstream targets of AMPK 
ACC and mTORC1 complex are two major downstream targets of AMPK. In 
CWR22Rv1 cells, Zyflamend (200 µg/ml) increased phosphorylation of ACC ~2 fold 
after 30 min treatment (Figure III.4A, B). The cellular level of acetyl CoA significantly 
increased by about 1.5 fold after 24 hr treatment of Zyflamend (Figure III.4C).  
Regarding mTORC1 complex which includes raptor and GβL [288], Zyflamend 
treatment increased phosphorylation of raptor ~4 fold after 30 min treatment (Figure 
III.4A, B). Phosphorylation of S6K, a downstream biomarker for activity of mTORC1 
complex, was reduced in a time dependent manner (0.5–3 hr) with Zyflamend treatment 
(Figure III.4A, B). In the presence of Zyflamend, GβL protein levels decreased in a time 
dependent manner (Figure III.4A, B). Increases in the phosphorylation of ACC and raptor  
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Figure III.2 Effects of Zyflamend on fatty acid oxidation. 
(A) Percent change in oxygen consumption rate (OCR) relative to baseline in 
CWR22Rv1 cells that were pre-treated with vehicle (olive oil) or Zyflamend (200 µg/ml). 
BSA or palmitate was injected at time point 0. Etomoxir (ETO) was injected at 55 
minutes. Palmitate oxidation (right panel) was determined by subtracting the OCR 
measurements before and after etomoxir injection. The resultant OCR from the BSA 
group is then subtracted from the resultant OCR from the palmitate group to get the 
relative palmitate oxidation that is expressed in arbitrary units (AU). (B) Percent change 
in oxygen consumption rate (OCR) relative to baseline in CWR22Rv1 cells that were 
pre-treated with vehicle (DMSO) or AICAR (100 µM). BSA or palmitate was injected at 
time point 0. Etomoxir (ETO) was injected at 55 minutes. Palmitate oxidation was 
determined as before (right panel). For palmitate oxidation measurements data points 
represent the average OCR (%) over 3-5 replicates per condition. Error bars are +/- SEM. 
Significant differences indicated (*, p < 0.05) 
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Figure III.3 The effects of Zyflamend on phosphorylation of AMPKα in CWR22Rv1 
and PC3 prostate cancer cell lines. 
 
(A, B) Protein levels of p-AMPKα were determined in CWR22Rv1 cells treated ± 
Zyflamend (200 µg/ml, 0-3 hr). Data is presented in (B) for the 30 min time point. (C, D) 
Protein levels of p-AMPKα were determined in PC3 cells treated ± Zyflamend (200 
µg/ml, 30 min). Data is presented as mean±SD, n=3. Group comparisons, Zyflamend 
versus control, * p<0.05 
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Figure III.4 Regulation of downstream targets of AMPK by ±Zyflamend in 
CWR22Rv1 cells. 
 (A, B) The effects of Zyflamend treatment (0.5–3 hr) on phosphorylation of ACC, raptor 
and S6K and protein levels of GβL. Data is presented as mean±SD, n=3. Group 
comparisons, Zyflamend versus control, * p<0.05. (C) Effects of Zyflamend on total 
cellular levels of acetyl CoA. Data is presented as mean±SD, n=3. Group comparisons, 
Zyflamend versus control, * p<0.05. 
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were recapitulated in CWR22Rv1 cells following treatment with the positive control 
AICAR (Figure III.5A, B) and in PC3 cells following treatment with Zyflamend (Figure 
III.5C, D).  
To confirm that Zyflamend increased phosphorylation of ACC and raptor by 
increasing the activity of AMPK, we knocked down AMPKα1/2 subunit by siRNA. 
Transit knockdown by siRNA transfection resulted in a 50% reduction of AMPKα 
protein levels (Figure III.6A, B). Concomitantly, phosphorylation of ACC and raptor was 
decreased by about 50% after AMPKα knockdown. The addition of Zyflamend treatment 
attenuated the effects of siRNA knockdown of AMPKα1/2 on phosphorylation of ACC 
and raptor (Figure III.6A, C, D).  
3.3.5 Zyflamend decreased CWR22Rv1 cell viability, in part, through the 
activation of AMPK 
Inhibiting AMPK activity by compound C modestly enhanced CWR22Rv1 cell 
viability after 48 hr treatment (Figure III.7A). Zyflamend decreased cell viability and this 
effect was attenuated with the concomitant treatment of compound C (Figure III.7A).  
To mimic the effect of Zyflamend’s induction of phosphorylation of AMPKα, 
cells were treated with AICAR, a known AMPK activator. AICAR (100 µM) treatment 
decreased cell viability by about 20% after 48 hr treatment. Treatment with AICAR plus 
Zyflamend resulted in an additional reduction in cell viability (~30%) (Figure III.7C).  
Overexpression of AMPKα1/2 subunits (as confirmed by western blot, Figure 
III.7B) inhibited cell viability in CWR22Rv1 cells by 40% (Figure III.7C), and this effect 
was augmented in the presence of Zyflamend.    
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Figure III.5 Regulation of downstream targets of AMPK by AICAR in CWR22Rv1 
cells and Zyflamend (Zyf) in PC3 cells. 
(A, B) The effects of AICAR (positive control) on phosphorylation of ACC and raptor in 
CWR22Rv1 cells. (C, D) The effects of Zyflamend on phosphorylation of ACC and 
raptor in PC3 cells. Data is presented as mean±SD, n=3. Group comparisons, AICAR or 
Zyflamend versus control,* p<0.05 
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Figure III.6 The effects of partial knockdown of AMPKα1/2 on phosphorylation of 
ACC and raptor in the presence or absence of Zyflamend. 
(A, C, D) Western blot of p-ACC and p-raptor following knockdown of AMPKα1/2 in 
the presence or absence of Zyflamend. Data is presented as mean±SD, n=3. 
a,b,c,d
Bars 
with different letters within each figure are significantly different at p< 0.05; (B) Group 
comparison, siAMPKα versus control,* p<0.05. 
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Figure III.7 The effects on modulating AMPK activity on cell viability with the 
AMPK inhibitor compound C and overexpression of AMPKα1/2 subunits in the 
presence or absence of Zyflamend in CWR22Rv1 cells. 
(A) The effects of cell viability following treatment with compound C, in the presence or 
absence of Zyflamend. Data is presented as mean±SD, n=8. 
a,b,c,d
 Bars with different 
letters are significantly different at p< 0.05. (B) Overexpression by adenovirus as 
confirmed by western blot. (C) The effects of overexpression of AMPKα1/2 subunits on 
cell viability in the presence or absence of Zyflamend. Data is presented as mean±SD, 
n=8. Bars with different letters (
a,b,c,d
 or 
A’,B’,C’
) are significantly different at p<0.05. 
Within group comparisons ±Zyflamend, * p<0.05.   
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3.4 Discussions 
Zyflamend is a commercial product comprised of the extracts of ten herbs. Its 
original formulation almost 2 decades ago was based on those herbs that had antioxidant 
and anti-inflammatory properties. Its subsequent use as a complementary therapy and 
experimental investigations in an assortment of cancer models has drawn attention by a 
variety of laboratories interested in the role of natural products in health and disease [175, 
176, 179-189, 250]. 
There are always concerns regarding reproducibility and quality control of 
complex commercial products. The quality control in the preparation of these extracts has 
been described in detail elsewhere [176]. Assurance of that quality control has been 
verified by the corroborative reproducible results generated at different times, with 
different lots, in multiple laboratories, under different circumstances, using similar and 
different cell lines with similar concentrations [175, 176, 179-189, 250]. The best 
combinations of extracts within this formulation have not been systematically determined 
because it would be infeasible to reproduce the results from 1028 possible combinations. 
However, recent evidence using biologic and molecular endpoints suggests that the 
condominium of compounds found in individual extracts is synergistically more 
efficacious than isolated bioactives derived from those extracts and that the combinations 
of extracts are synergistically more efficacious than the extracts used individually [286]. 
These combinations are more likely to have bioactivity at concentrations that would be 
more physiologically relevant [286]. Furthermore, the use of well-defined extracts in 
testing mechanisms of action provides evidence more related to how people eat (viz. 
people eat foods with their complexity of bioactives, not purified compounds from those 
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foods).  As such, generating mechanisms of action using well-defined combinations 
should further the understanding of the food-health relationship. 
In our laboratory, we have been studying the effects of Zyflamend on preclinical 
models of castrate-resistant prostate cancer [175, 176, 182] using cell lines derived from 
the CWR22 lineage [289, 290]. We focus our attention on this lineage because the 
androgen dependent CWR22 cells can relapse into the androgen-insensitive CWR22R 
cell line in vivo following androgen deprivation [290, 291]. These cells, unlike the 
androgen independent PC3 cell line, have a functional androgen receptor and produce 
prostate specific antigen, common characteristics in human castrate-resistant prostate 
cancer.  
Our experience using Zyflamend and those of others [175, 176, 179-189, 250] 
reveal diverse mechanisms of action, possibly explaining its robust effects using in vivo 
models of tumorigenesis at oral doses that mimic human intakes [176, 189]. To further 
investigate this diversity of action, the objective of this study was to follow up on our 
preliminary evidence that Zyflamend also inhibits lipogenesis by down regulating 
SREBP-1c and FASN expression and enhancing fatty acid oxidation. To support the 
rapid proliferation of cancer cells, upregulation of de novo fatty acid synthesis is 
commonly found in solid tumors, including prostate, and this metabolic shift supporting 
anabolic processes can be the result of dysregulation of AMPK [237, 238]. Therefore, we 
logically investigated the effect of Zyflamend on AMPK activation as determined by 
modulation of its well-accepted downstream targets involved in lipogenesis and 
mTORC1 signaling. 
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AMPK is a multimeric protein consisting of a catalytic subunit (α) and two 
regulatory subunits (β and γ) [235]. Activation of AMPK involves the phosphorylation of 
Thr172 of the α subunit. Activation of this kinase increases catabolic pathways such as 
fatty acid oxidation, and inhibits anabolic pathways such a lipogenesis and protein 
synthesis [292]. Regulation of AMPK has become an important target for cancer 
treatment. AMPK activators, such as MT63-78, metformin and AICAR, have been shown 
to be inhibitors of prostate cancer in a variety of preclinical models [238, 244].  
Zyflamend increased AMPK activity by increasing phosphorylation of Thr172 of 
the catalytic subunit, resulting in inhibition of fatty acid synthesis, in part, via the 
phosphorylation of ACC. Importantly, de novo phospholipid biosynthesis has been 
shown to be a primary target for fatty acids from this pathway [238]. These results are 
consistent with previous studies investigating AMPK activation using a variety of 
prostate cancer cell lines, where  multiple AMPK activators increased phosphorylation of 
AMPK, ACC, raptor, and inhibited phosphorylation of S6K [238]. Furthermore, our 
results demonstrating increases in fatty acid oxidation are also consistent with AMPK  
activation as determined by C
14
-CO2 production using in vivo and in vitro models of 
prostate cancer [238].  Collectively, these results suggest that Zyflamend was causing a 
shift in anabolic and catabolic processes. 
Recapitulation of AMPK activation was demonstrated via the inhibition of 
mTORC1 signaling, and our results are similar to those of others who used a variety of 
tools to activate AMPK [238, 244]. Knock down and over-expression experiments and 
the use of AICAR and compound c confirmed Zyflamend’s role in regulating AMPK 
activation and its downstream signaling.  
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In an effort to determine how Zyflamend was regulating AMPK, we ran some 
preliminary experiments using inhibitors of LKB1 and CaMKKβ, kinases known to be 
involved in the phosphorylation of Thr172 [235] (Figure III.8). Zyflamend increased the 
phosphorylation of LKB1 and AMPK. Inhibiting LKB1 with radicicol reduced basal 
levels of p-AMPKα and appeared to attenuate the ability of Zyflamend to fully 
phosphorylate AMPKα. The CaMKKβ inhibitor STO-609 could also inhibit the 
phosphorylation of AMPK, but Zyflamend was able to fully rescue AMPK 
phosphorylation in the presence of STO-609, suggesting the increase in AMPK 
phosphorylation is mediated in part via LKB1. Follow up experiments are needed to fully 
explore this mechanism. Furthermore, we previously reported that Zyflamend was a 
potent inhibitor of the expression of PSA [176] and androgen receptor [176, 182], along 
with increases in p21 expression [175], and recent data have strongly suggested that these 
results may also be linked to AMPK activation [238]. Castrate resistant forms of the 
disease coordinately involve activation of the androgen receptor in the absence of 
androgens coupled with higher expression of lipogenic genes compared with prostate 
cancer cells that are androgen-dependent [217, 238, 293]. 
Bioactives from natural products found in Zyflamend, such as resveratrol, 
berberine, curcumin, epigallocatechin gallate, etc, have been shown to be potential 
activators of AMPK [233]; however, the levels needed are in the range of 10-100 μM , or 
3-4 orders of magnitude higher than physiologically possible [286, 294-298]. In order to 
identify components within Zyflamend that could account for these results (at least in 
part), we investigated the effects of berberine and curcumin, compounds in Chinese 
goldthread and turmeric, respectively (Figure III.9). Each compound in isolation and in  
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Figure III.8 Zyflamend may activate AMPK partially via activation of LKB1. 
 
(A, B) Western blot of p-LKB1 following treatment of Zyflamend in CWR22Rv1 cells. 
Group comparison, Zyflamend versus control,* p<0.05. (C) Western blot of p-AMPKα 
following treatment of radicicol (LKB1 inhibitor) (D) The effects of STO-609 (CaMKKβ 
inhibitor) on phosphorylation of AMPKα in the presence or absence of Zyflamend. Data 
is presented as mean±SD, n=3. 
a,b,c
 Bars with different letters are significantly different at 
p< 0.05. 
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Figure III.9 Berberine and curcumin activate AMPK and downstream targets. 
(A) Western blot of p-ACC, p-raptor and p-AMPKα following treatment of berberine or 
curcumin in CWR22Rv1 cells. (B) Western blot of p-ACC, p-Raptor and p-AMPKα 
following treatment of combination of berberine and curcumin in CWR22Rv1 cells. 
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combination increased AMPK activation; results not all that different from our earlier 
findings with the inhibition of NF-κB activation and cell proliferation in the same 
experimental model [286].   
In summary, Zyflamend is a polyherbal mixture whose components have been 
shown to act synergistically against cancer in a variety of models. It has been clearly 
established that activation of AMPK can inhibit mTORC1 signaling, the expressions of 
androgen receptor, p21, SREBP-1c and FASN, ACC activity, and increase fatty acid 
oxidation. Zyflamend also replicates these same effects. In addition to inhibiting the 
expression of androgen receptor and p21, the results presented here also suggest that it 
coordinately up regulates AMPK activation as evidenced by inhibition of mTORC1 
signaling, the expressions of SREBP-1c, FASN, and ACC activity, with increases in fatty 
acid oxidation. Based on these results and those previously published in other cancer 
models, combinations of natural products, such as those found in Zyflamend, should be 
considered for complementary therapy due to their potential multiple mechanisms of 
action. 
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CHAPTER IV  
CONCLUSIONS 
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Most of today’s cancers are influenced by our environment, particularly by the 
botanicals we eat (i.e., herbs, fruits, vegetables). The major source of bioactive 
phytonutrients is from these foods. To understand the impact of their consumption, our 
objective was to investigate the concept that the combination of bioactives in botanicals 
is potentially far more effective than an individual bioactive in isolation. Our data is 
proof-of-principle that combinations of companion bioactives from the same source and 
bioactives from different sources act synergistically, providing some evidence that 
combinations found in botanicals (and foods) have advantages over isolated bioactives. 
Even compounds with poor efficacy can become more biologically active in the presence 
of companion compounds. These advantages translate into effective doses those are more 
physiologic.  
Zyflamend is a polyherbal mixture whose components have been shown to act 
synergistically against cancer in a variety of models. It has been clearly established that 
activation of AMPK can inhibit mTORC1 signaling, the expressions of androgen receptor, 
p21, SREBP-1c and FASN, ACC activity, and increase fatty acid oxidation. Zyflamend 
also replicates these same effects. In addition to inhibiting the expression of androgen 
receptor and p21, the results presented here also suggest that it coordinately up regulates 
AMPK activation as evidenced by inhibition of mTORC1 signaling, the expressions of 
SREBP-1c, FASN, and ACC activity, with increases in fatty acid oxidation. Based on 
these results and those previously published in other cancer models, combinations of 
natural products, such as those found in Zyflamend, should be considered for 
complementary therapy due to their potential multiple mechanisms of action. 
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